Meet Ernest Hawk, M.D.
Ernest Hawk, M.D., M.P.H.
Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences
About Dr. Hawk
Ernest Hawk, M.D., MPH, is vice president and head of the division of Cancer Prevention and Population Sciences at The University of Texas MD Anderson Cancer Center and holds the T. Boone Pickens Distinguished Chair for Early Prevention of Cancer. Additional responsibilities include leadership of the Duncan Family Institute for Cancer Prevention and Risk Assessment and co-leadership of MD Anderson’s Cancer Prevention and Control Platform which advances community health promotion and cancer control through evidence-based public policy, public and professional education, and community-based service implementation and dissemination.
A native of Detroit, Michigan, Dr. Hawk earned his medical degree from Wayne State University and his Master of Public Health degree at Johns Hopkins University. He completed an internal medicine internship and residency at Emory University, a medical oncology clinical fellowship at the University of California, San Francisco, and a cancer prevention fellowship at the National Cancer Institute (NCI).
Prior to his appointment at MD Anderson in December 2007, Dr. Hawk held several positions at the NCI in Bethesda, MD. He most recently served as director of the Office of Centers, Training and Resources, responsible for the NCI’s cancer centers program, a major translational science program (i.e., the SPORE program), the NCI’s extramural training enterprise, and its extramural disparities portfolio. His prior NCI posts included chief and medical officer of the Gastrointestinal and Other Cancers Research Group, medical officer in the Chemoprevention Branch, and chair of the Translational Research Working Group.
Dr. Hawk has been involved in a wide range of preclinical and clinical chemoprevention research, including developmental studies of nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, and preventive agent combinations in high-risk cohorts. Interests include the improvement of minority and medically underserved populations’ participation in clinical research, future applications of multi-cancer early detection tests, and the integration of risk assessment, behavioral science, and preventive strategies developed through sequential clinical trials for application in clinical or public health settings. He has published more than 180 scientific articles and book chapters, edited three books, serves as an editor of Holland & Frei’s Cancer Medicine (10th edition), and serves as the senior deputy editor for Cancer Prevention Research, and on the editorial board of Cancer Medicine.
Dr. Hawk can be reached at 713-792-3900 or through his Office Manager, Wendy McDaniel at 713-745-0490 or via email (wcmcdaniel@mdanderson.org)
In the News
Asbestos exposure and cancer: 8 things to know
What are multi-cancer early detection (MCED) tests, and should you get one?
Artificial sweeteners and cancer: 7 things to know
Radon exposure and lung cancer: 11 things to know
How MD Anderson’s Moon Shots Program is working to end cancer through prevention
Present Title & Affiliation
Primary Appointment
Co-Director, Department of CCSG, Community Outreach and Engagement Component, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Boone Pickens Distinguished Chair for Early Prevention of Cancer, Department of Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX
Executive Director, Duncan Family Institute for Cancer Prevention and Risk Assessment, Department of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Vice President, Department of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Division Head, Department of Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Director, Department of CCSG, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Division of Cancer Prevention & Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Cancer Prevention and Control
Translational Research
Molecular Intersections between Cancer and Other Diseases
Education & Training
Degree-Granting Education
| 1994 | Johns Hopkins University School of Hygiene & Public Health, Baltimore, MD, US, Epidemiology/Biostatistics, Masters of Public Health |
| 1985 | Wayne State University School of Medicine, Detroit, MI, US, Medicine, Medical Doctorate |
| 1981 | Wayne State University, Detroit, MI, US, Biological Sciences, Bachelor of Science |
Postgraduate Training
| 2025-2025 | Ethics Training for Special Government Employee, Department of Health & Human Services, Washington, D.C, District of Columbia |
| 2024-2024 | Certified Tobacco Treatment Specialist, Tobacco Treatment Training Certificate Program, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2008-2009 | Advanced Professional Training, Faculty Academic Leadership, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 1993-1996 | Research Fellowship, Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, MD |
| 1991-1993 | Clinical Fellowship, Medical Oncology, University Of California, San Francisco |
| 1985-1988 | Clinical Internship and Residency, Internal Medicine, Emory University Affiliated Hospitals, Atlanta, GA |
Board Certifications
| 2013 | American Board of Internal Medicine - Medical Oncology |
| 2003 | American Board of Internal Medicine - Recertification in Medical Oncology |
| 1993 | American Board of Internal Medicine - Diplomate in Medical Oncology |
| 1988 | American Board of Internal Medicine - Diplomate in Internal Medicine |
| 1986 | National Board of Medical Examiners - Diplomate |
Experience & Service
Academic Appointments
Director, Department of Office of the Director, National Cancer Institute, Bethesda, MD, 2004 - 2007
Chief & Medical Officer, Department of Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, 1999 - 2004
Medical Officer, Department of Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, 1997 - 1999
Special Expert (Translational Cancer Prevention), Department of Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, 1996 - 1997
Administrative Appointments/Responsibilities
Associate Director, Department of CCSG, Community Outreach and Engagement Component, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2024
Department Chair ad interim, Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2016
Co-Director, Department of Moonshot Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2024
Department Chair ad interim, Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2011
Associate Director, Department of CCSG, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - Present
Department Chair ad interim, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2009
Division Head, Department of Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - Present
Other Appointments/Responsibilities
Ad Hoc Advisory Consultant, CCSG P30 grant renewal, Northwestern University, Chicago, IL, 2025 - Present
Consultant (Unpaid), Shield™ Blood Test for Colorectal Cancer (CRC) Screening, Guardant Health, Palo Alto, CA, 2024
Extramural Reviewer, Division Head Appointment Review, DKFZ Hector Cancer Institute at University Medicine Mannheim, Heidelberg, 2024
Member (offered), Expert Review Panel, Cancer Research UK, London, 2024
Member, Scientific Advisory Board, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Member, External Scientific Review Committee for the DKFZ (German National Cancer Research Center), Helmholz Foundation, Heidelberg, 2024 - 2025
External Advisory Board, U54 SPORE on the Biology of Colorectal Cancer Disparities, Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, OK, 2024 - Present
Member, Innovation Council, Prevent Cancer Foundation, Alexandria, VA, 2023 - Present
Co-chair, External Scientific Advisory Board, Mayo Clinic, Rochester, MN, 2023 - Present
Member, Task Force to Advance the Care of Sexual and Gender Minority Cancer Patients, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - Present
Consultant (paid to MD Anderson), Multi-cancer early detection device development, Exact Sciences, Madison, WI, 2022 - Present
Member, External Advisory Board, Medical University of South Carolina, Charleston, SC, 2021 - Present
Member, External Advisory Board, Oregon Health Sciences University, Portland, OR, 2021 - Present
Member, External Advisory Board for the Virginia Survivor Cohort, Virginia Commonwealth University, Richmond, VA, 2020 - 2021
At-Large Member, Women's Leadership Network Steering Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2023
Member, Lung Moonshot Executive Steering Committee, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Member, External Advisory Board, University of Alabama at Birmingham, Birmingham, AL, 2020 - Present
Champion, Diversity, Equity, and Inclusion, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2023
Chair, External Scientific Advisory Board, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, 2020
Extramural advisory, Search Committee for the Director of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, 2019 - 2020
Member, External Advisory Board, Virginia Commonwealth University, Richmond, VA, 2019 - 2023
Member, Strategic Planning Working Group (ad hoc), National Cancer Institute, Bethesda, MD, 2019
Member, Advisory Group on Multicancer Early Detection Tests - Potential Development Strategies and Uses, Mayo Clinic, Rochester, MN, 2019 - 2021
Member, Howard-Hopkins Partnership Steering Committee (PSC), Sidney Kimmel CCC & Howard University Cancer Center, Baltimore, MD, 2019 - 2020
Member, External Advisory Board, Rutgers University, New Brunswick, NJ, 2019 - Present
Member, Clinical and Translational Research Advisory Committee (CTAC), National Cancer Institute, Bethesda, MD, 2019 - 2024
Chair, Community Outreach and Engagement External Advisory Board, Mayo Clinic Cancer Center, Rochester, MN, 2019
Co-Chair, Internal Advisory Committee, University of Puerto Rico and the University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present
Member (ad hoc), External Advisory Committee, University of Wisconsin-Madison, Madison, WI, 2018 - 2020
Member, NCI Ideas Workshop, National Cancer Institute, Bethesda, MD, 2018 - 2019
Member, Physician Scientist Oncology Training Program - External Advisory Committee, UT Southwestern Medical Center, Dallas, TX, 2018 - 2020
Member, External Scientific Advisory Committee, Albert Einstein Cancer Center, Bronx, NY, 2018 - 2020
Member, External Advisory Panel (ad hoc), Fred Hutchinson Cancer Research Center, Seattle, WA, 2017
Member, External Advisory Board, Johns Hopkins University, Baltimore, MD, 2017 - Present
Co-Chair, Cancer Prevention Steering Committee, National Cancer Institute, Bethesda, MD, 2017 - 2023
Member, External Advisory Panel, University of New Mexico, Albuquerque, NM, 2017 - 2024
Participant, Biden's Cancer Moonshot initiative, Blue Ribbon Panel Working Group on Precision, Prevention and Early Detection, Washington, DC, 2016 - 2018
Member, External Advisory Board, University of Nebraska Medical Center, Omaha, NE, 2015 - Present
Member, Board of Directors, MD Anderson Physicians Network (MDAPN), Houston, TX, 2015 - 2016
Member, Gastric and Esophageal Cancers Working Group, National Cancer Institute, Bethesda, MD, 2015 - 2018
Member, Board of Directors, CATCH Global Foundation, Austin, TX, 2015 - 2024
Invited Member, Models Across Miles - Partnership Strategies for Regional Health Improvement, The University of Texas System, Austin, Texas, 2014
Member, Cancer Center Director Search Committee, University of Texas - Austin, Austin, TX, 2014 - 2015
Member, Advisory Board, Pozen Pharmaceutical Development Company, Raleigh, NC, 2013 - 2014
Member, Process of Care Research Branch (PCRB) Working Group, National Cancer Institute, Rockville, MD, 2012 - 2017
Member, External Advisory Board, The University of Texas - Southwestern, Dallas, TX, 2011 - Present
Consultant, External Cancer Research Review and Center Planning, University of Illinois - Chicago, Chicago, IL, 2010 - 2013
Consultant, Special Government Employee (SGE), Oncologic Drugs Advisory Committee (ODAC), Food and Drug Administration, Silver Springs, MD, 2010 - 2015
Consultant and committee member, Multilevel Interventions Across the Cancer Care Continuum Committee, National Cancer Institute, Rockville, MD, 2010 - 2013
Moderator, Translational Science Meeting, National Cancer Institute, Vienna, VA, 2009
Member, Editorial Advisory Board, Prevention Magazine, Emmaus, PA, 2009 - 2014
Member, Process to Accelerate Translational Science Working Group (PATS WG), National Cancer Institute, Bethesda, MD, 2009 - 2013
Member, CCSG External Advisory Board (ad hoc), University of Arizona Cancer Center, Tucson, AZ, 2009
Member, Scientific Steering Committee, Coxib and Traditional NSAID Trialists' (CNT) Collaboration, Oxford, 2009 - 2013
Member, External Advisory Board, Roswell Park Cancer Institute, Buffalo, NY, 2008 - Present
Member, External Advisory Board, University of Utah, Salt Lake City, UT, 2008 - Present
Member, External Scientific Advisory Board, Ohio State University Comprehensive Cancer Center - James Cancer Hospital, Columbus, OH, 2008 - 2017
Panelist, Translational Science, Indiana Health Industry Forum - Oncology Summit, Indianapolis, IN, 2008
Member, External Advisory Board, Mayo Clinic, Rochester, MN, 2008 - Present
Member, Extramural Scientific Advisory Committee, Harris County Hospital and University National Children's Study, Houston, TX, 2008 - 2013
Special Advisor on Cancer Prevention, Cancer Institute of New Jersey, Somerset, NJ, 2008
Member, External Advisory Board, University of Kansas, Kansas City, KS, 2008 - Present
Advisor, National Cancer Prevention Initiative, National Cancer Institute of Canada and Canadian Cancer Society, Toronto, Ontario, 2006 - 2008
Executive Secretary, National Cancer Advisory Board - Cancer Centers Subcommittee, National Cancer Institute, Bethesda, MD, 2005 - 2007
Co-chair, Translational Research Working Group, National Cancer Institute, Bethesda, MD, 2005 - 2007
Member, Executive Committee, National Cancer Institute, Bethesda, MD, 2004 - 2007
Co-Leader, Scientific Advances Symposium Planning Project Team, National Cancer Institute, Bethesda, MD, 2002 - 2003
Facilitator, SPORE (P50) Program - Colorectal Cancer Research Program, National Cancer Institute, Bethesda, MD, 2002 - 2004
NCI Representative, Secretary's Initiative on Colorectal Cancer, Department of Health and Human Services, Bethesda, MD, 2002 - 2003
Executive Director, Stomach and Esophageal Cancer Progress Review Group, National Cancer Institute, Bethesda, MD, 2001 - 2005
Member, Flat Adenoma and ACF Project Team, National Cancer Institute, Bethesda, MD, 2001 - 2002
Member, Cancer Prevention Scientific Education Committee, National Cancer Institute, Bethesda, MD, 2000 - 2001
Member, Prevention of Languishing Studies Project Team, National Cancer Institute, Bethesda, MD, 2000 - 2001
Member, Clinical Trials Project Team, National Cancer Institute, Bethesda, MD, 2000 - 2001
Co-Chair, Working Group on Barrett's-associated Cancer, National Cancer Institute and National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2000 - 2002
Member, Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Scientific Coordination & Oversight Panel, National Cancer Institute, Bethesda, MD, 1999 - 2005
Member, Coordinating Unit, National Cancer Institute, Bethesda, MD, 1999 - 2005
Member, Committee on Public Educational Materials for Cancer Prevention, National Cancer Institute, Bethesda, MD, 1997 - 1998
Ad Hoc Member, Community Clinical Oncology Program - Prevention & Control Concept & Protocol Review Committees, National Cancer Institute, Bethesda, MD, 1996 - 2005
NCI Divisional Representative, International Common Toxicity Criteria Revision Committee (Version 2.0), National Cancer Institute, Bethesda, MD, 1996 - 1997
Member and Chair, Source Evaluation Groups for Phase II Chemoprevention Trials, National Cancer Institute, Bethesda, MD, 1994 - 1999
Ad Hoc Member, Chemoprevention Safety and Protocol Review Committee, National Cancer Institute, Bethesda, MD, 1994 - 2005
Member, Chemoprevention Agent Development Committee, National Cancer Institute, Bethesda, MD, 1994 - 2005
Institutional Committee Activities
Member, Selection Committee, German Prize for Cancer Prevention Research 2025, 2025 - Present
Member, AACR-Women in Cancer Research Charlotte Friend Lectureship Award, 2025 - 2026
Member, Executive Committee, iCAN-PREVENT: MD Anderson International Cancer Prevention Clinical Trial Consortium, 2024 - Present
Member, Texas Health Equity Alliance for Breast Cancer (THEAL) Internal Advisory Committee, 2023 - Present
Past Chair, Division Heads, 2023 - 2024
Member, Texas Business Women's Nominee Review Committee, 2022 - 2023
Observer/Advisor, Policy Management System Renovation Project Selection Committee, 2022 - Present
Chair, Division Heads, 2022 - 2023
Co-Chair, Rogers Award Selection Committee - Prevention, 2021
Member, Academic Policy Advisory Council, 2021 - Present
Member, Cancer Screening Task Force, 2021 - Present
Member, Global Oncology Strategy Workgroup, 2021 - Present
Team Lead - Clinical Prevention Services, Service Line Teams, 2021 - Present
Member, Research Enablement, Activities and Conduct Team (REACT), 2021 - Present
Member, Research Policy Advisory Council, 2021 - Present
Incoming Chair, Division Heads, 2021 - 2022
Member, Strategic Position Management Committee - Classified research and education positions, 2020 - 2023
Member, Promoting HPV Vaccination Among Texas Young Adults, 2020 - 2023
Faculty Co-Lead, Board of Visitors Cancer Prevention Committee, 2020 - 2024
Member, Strategic Position Management Committee, 2020 - 2022
Member, Sarcoma SPORE, 2019 - Present
Division Head for Cancer Prevention & Population Sciences, Division Heads, 2018 - Present
Member, Quasi-Endowment for the Underserved (COE Fund), 2018 - Present
Member, President's Advisory Committee, 2018 - Present
Member, Mexican-American Cohort Study, 2018 - Present
Member, Network Advisory Committee, 2018 - 2022
At-Large Member, Women's Leadership Network Steering Committee, 2018 - 2022
Member, Internal Advisory Board, 2018 - 2021
Member, Executive Committee, Komen Training Program to Reduce Breast Cancer Disparities in Black and Hispanic Women, 2018 - 2020
Member, Shared Resource Executive Committee, 2017 - 2019
Member, Institutional Biospecimen Utilization Committee (IBUC), 2017 - 2022
Co-Chair, Clinician Scientist Advisory Committee, 2017
Member, Women and Minority Faculty Inclusion, 2016 - 2023
Member, Head & Neck SPORE (P50), 2016 - Present
Chair, HPV SPORE (P50), 2016 - 2018
Chair, 2016 Rogers Award, 2016
Co-leader and Convener, CCSG Community Outreach & Engagement Leaders Team, 2016 - 2022
Member, International Cancer Control Partnership Steering Committee, 2015 - 2022
Member, MD Anderson Communications Advisory Committee, 2015 - 2017
Member, Executive Clinical Operations Team, 2015 - 2019
Member, Prostate Cancer SPORE (P50), 2014 - 2021
Team Member, Translational Research Strategic Planning Committee, 2014 - 2016
Member, Women Faculty Programs' Advisory Committee, 2014 - 2016
Member, GAP 2015 Conference, 2014 - 2015
Member, Cancer Medicine Division Head Search Committee, 2014 - 2015
Member, GAP International Advisory Board, 2014 - 2016
Member, Medical Quality Planning Committee, 2014 - 2019
Member, Clinical/Translational Awards Committee, 2013 - 2016
Member, Institutional Research Executive Committee (IREC), 2013 - 2015
Co-Chair, Internal Medicine Division Head Search Committee, 2013 - 2014
Member, Head and Neck Cancer SPORE (P50), 2013 - Present
Member, Institute for Cancer Care Excellence, 2012 - 2017
Member, Standing Committee on Faculty Awards, 2012 - Present
Member, Thoracic Head and Neck Medical Oncology Chair Search Committee, 2012 - 2013
Member, EVP and Provost Search Advisory Committee, 2012 - 2013
Member, David H. Koch Center for Prostate Cancer, 2012 - 2017
Member, Research Station, 2012 - 2014
Member, External Communications Advisory Committee, 2012 - 2017
Member, Institutional Clinical Executive Committee, 2011 - 2015
Member, Epidemiology Search Committee, 2011 - 2013
Session Co-Chair, Annual Symposia on Cancer Research, 2010
Co-Chair, Cancer Control Leadership Team, 2010 - 2024
Member, Molecular Testing Evaluation Committee, 2010 - Present
Co-Leader, GI Cancer Research Program, 2010 - 2022
Member, MD Anderson Survival Monograph Editorial Board, 2009
Member, Institutional Awards Committee, 2009 - Present
Chair, Comparative Effectiveness Research Grants Review Committee, 2009 - 2011
Chair, Duncan Institute Executive Committee, 2009 - Present
Member, Global Academic Programs Oversight Steering Committee, 2009 - 2014
Member, Margaret L. Kripke Legends Award, 2008 - Present
Member, Institute of Personalized Cancer Therapy (IPCT), 2008 - 2015
Member, Infrastructure/Animal Care Committee, 2008 - 2010
Member, 2008 Rogers Award, 2008
Member, Management Committee, 2008 - 2011
Member, Division Heads Committee, 2008 - 2012
Member, Cancer Prevention Research Training Program Advisory Committee, 2008 - Present
Member, Research Council, 2007 - 2013
Member, Research Strategies Advisory Committee, 2007 - 2012
Member, Executive Committee of the Medical Staff, 2007 - Present
Member, Translational Research Faculty Development Committee, 2007 - 2012
Member, CCSG Executive Committee, 2007 - Present
Member, Extramural Programs Oversight Steering Committee, 2007 - 2014
Member, PRS Executive Council, 2007 - Present
Member, Clinical Strategies Advisory Committee, 2007 - 2012
Member, President's Advisory Board, 2007 - 2015
Member, Clinical Research Council, 2007 - 2011
Honors & Awards
| 2015 | 2015 Provost's Distinguished Faculty Mentor Nominee, The University of Texas MD Anderson Cancer Center |
| 2015 | ASCO/American Cancer Society Award and Lecture, ASCO/American Cancer Society |
| 2014 | Cancer Prevention Fellowship Distinguished Alumni Award, National Cancer Institute, Department of Health & Human Services |
| 2013 | Eagle Award, Cancer Fighters of Houston, Inc |
| 2011 | Outstanding Leading Mentor in Cancer Prevention, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center |
| 2007 | On-the-Spot Award, National Cancer Institute |
| 2007 | The Nancy Terner Behrman Lecture in Honor of Betty Flehinger, PhD, Weill Cornell Medical School, NYC |
| 2003 | Service Award, National Cancer Institute |
| 2002 | On-the-Spot Award, National Cancer Institute |
| 2002 | Research Award, Distinguished Achievement in Cancer Prevention, National Cancer Institute |
| 2002 | Research Award, PLCO Ancillary Studies Project Team (Group Award), National Cancer Institute |
| 1999 | On-the-Spot Award, National Cancer Institute |
| 1998 - 2000 | Performance Awards, Department of Health and Human Services |
| 1996 | Scholarship, AACR/ASCO (First Joint) Workshop - Methods in Clinical Cancer Research, Park City, Utah |
| 1994 | Delta Omega Public Health Honor Society, Johns Hopkins Alpha Chapter |
| 1986 - 1988 | Outstanding, Emory University - Annual House Staff Evaluation Committee designations |
| 1985 | Outstanding, Emory University - Annual House Staff Evaluation Committee Designations |
| 1981 | Phi Beta Kappa, Wayne State University |
| 1977 - 1981 | Honors Program, Wayne State University, College of Liberal Arts |
| 1977 - 1981 | Scholarship (Full Tuition), Wayne State University |
| 1977 | Valedictorian, Madison High School |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Fokom Domgue J, Yu R, Hawk E, Shete S. Public awareness of the association between alcohol and cancer in the US. JAMA Oncol. e-Pub 2025. PMID: 40440050.
- Hurst A, Karam-Hage M, Cofer J, Javaid M, Beneventi D, Blalock J, Winter T, Cinciripini PM, Hawk E. A tobacco treatment training program expands the number of healthcare providers trained to use evidence-based practices and methods. ACEQI 1(1), 2025. e-Pub 2025.
- Ebbert JO, Hawk ET, Chambers CV, Tempero MA, Fishman EK, Ravenell JE, et al.. Multi-cancer early detection tests: Attributes for clinical implementation. Cancer Biomark 42(2):18758592241297849, 2025. e-Pub 2025. PMID: 40171802.
- Faupel-Badger J, Kohaar I, Bahl M, Chan AT, Campbell JD, Ding L, De Marzo AM, Maitra A, Merrick DT, Hawk ET, Wistuba II, Ghobrial IM, Lippman SM, Lu KH, Lawler M, Kay NE, Tlsty TD, Rebbeck TR, Srivastava S, Precancer Think Tank Team. Defining precancer: a grand challenge for the cancer community. Nat Rev Cancer 24(11):792-809, 2024. e-Pub 2024. PMID: 39354069.
- Kwan S, Gonzales KA, Jamal MA, Stevenson HL, Tan L, Hawk ET, et al. Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism. Gut Microbes 16(1), 2024. e-Pub 2024. PMID: 39239875.
- Love, B, Coffman, R, Ghosh, C, Cofer, J, Hurst, A, Hawk, E, et al. Implementation and Evaluation of a Multi-level, Place-Based Tobacco Prevention and Control Program at a Minority-Serving Institution in Texas. Prevention Science 25(6):898-909, 2024. e-Pub 2024. PMID: 39060839.
- Schrank BR, Fuller JA, Gallagher CM, Morris VK, Holliday EB, Hawk E, et al. Institution-wide retreats foster organizational learning and action at a comprehensive cancer center. J Cancer Educ 39(4):368-373, 2024. e-Pub 2024. PMID: 38468110.
- Hassan MM, Li D, Han Y, Byun J, Hatia RI, Hawk, E, et al. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology 80(1):87-101, 2024. e-Pub 2024. PMID: 38381705.
- Torres HA, Mustafayev K, Juneau RP, Hwang JP, Wang LS, Hawk E, et al. Implementation of universal hepatitis c virus screening in a tertiary cancer center. J Natl Compr Canc Netw 22(2D):e237332, 2024. e-Pub 2024. PMID: 38729204.
- Rechis R, Oestman KB, Walsh MT, Love B, Hawk E. Be Well™ Acres Homes: A community-driven, evidence-based approach to reduce health inequities through sustained cross-sector partnership. Cancer Causes Control 35(4):611-622, 2024. e-Pub 2024. PMID: 37979072.
- Oestman, KB, Rechis, R, Williams, PA, Brown, JA, Treiman, K, Hawk, E, et al. Reducing risk for chronic disease: evaluation of a collective community approach to sustainable evidence-based health programming. BMC Public Health 24(1):240, 2024. e-Pub 2024. PMID: 38245669.
- Deng N, Reyes-Uribe L, Fahrmann JF, Thoman WS, Munsell MF, Hawk ET, et al. Exercise training reduces the inflammatory response and promotes intestinal mucosa-associated immunity in Lynch syndrome. Clin Cancer Res 29(21):4361-4372, 2023. e-Pub 2023. PMID: 37724990.
- Batman SH, Varon ML, Daheri M, Ogburn T, Rivas SD, Hawk E, et al. Addressing cervical cancer disparities in Texas: Expansion of a community-based prevention initiative for medically underserved populations. Prev Med Rep 36:102486, 2023. e-Pub 2023. PMID: 38021412.
- Hatia RI, Eluri M, Hawk ET, Shalaby A, Karatas E, Shalaby A, et al. Independent of primary sclerosing cholangitis and cirrhosis, early adulthood obesity is associated with cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev 32(10):1338-1347, 2023. e-Pub 2023. PMID: 37540502.
- Maresso KC, Maitra A, Hawk E, Vilar E. From premalignant biology to precision interception: connecting the dots with a curated collection of invited articles. Cancer Prev Res (Phila) 16(7):365-68, 2023. e-Pub 2023. PMID: 37403656.
- Bello RS, Bello RS, Walsh MT, Walsh MT, Harper B, Harper B, Amos CE, Amos CE, Oestman K, Oestman K, Hawk E, Hawk E, et al, et al. Creating and activating an implementation community to drive HPV vaccine uptake in Texas: The role of an NCI-designated cancer center. Vaccines (Basel) 11(6), 2023. e-Pub 2023. PMID: 37376517.
- Salcedo MP, Gowen R, Rodriguez AM, Fisher-Hoch S, Daheri M, Hawk E, et al. Addressing high cervical cancer rates in the Rio Grande Valley along the Texas-Mexico border: a community-based initiative focused on education, patient navigation, and medical provider training/telementoring. Perspect Public Health 143(1):22-28, 2023. e-Pub 2023. PMID: 34130548.
- Torode JS, Tittenbrun Z, Romero Y, Johnson SE, Bourque JM, Hawk E, et al. Ten years of the international cancer control partnership: promoting national cancer control plans to shape the health system response for cancer control. JCO Glob Oncol 9, 2023. e-Pub 2023. PMID: 36630665.
- Fokom Domgue J, Pande M, Yu R, Manjuh F, Welty E, Hawk E, et al. Development, implementation, and evaluation of a distance learning and telementoring program for cervical cancer prevention in Cameroon. JAMA Netw Open 5(11), 2022. e-Pub 2022. PMID: 36346631.
- Berenson AB, Chang M, Hawk ET, Ramondetta LM, Hoang T. Vulvar cancer incidence in the US and its relationship to human papillomavirus vaccinations, 2001-2018. Cancer Prev Res (Phila) 15(11):777-784, 2022. e-Pub 2022. PMID: 35969832.
- Kwan SY, Sabotta CM, Joon A, Wei P, Petty LE, Hawk ET, et al. Gut microbiome alterations associated with diabetes in Mexican Americans in South Texas. mSystems 7(3):e0003322, 2022. e-Pub 2022. PMID: 35477306.
- Kwan SY, Jiao J, Joon A, Wei P, Petty LE, Hawk ET, et al. Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease. Hepatology 75(4):955-967, 2022. e-Pub 2022. PMID: 34633706.
- Kisiel JB, Papadopoulos N, Liu MC, Crosby D, Srivastava S, Hawk ET. Multicancer early detection test: Preclinical, translational, and clinical evidence-generation plan and provocative questions. Cancer 128 Suppl 4(S4):861-874, 2022. e-Pub 2022. PMID: 35133659.
- Jiao J, Kwan SY, Sabotta CM, Tanaka H, Veillon L, Hawk ET, et al. Circulating fatty acids associated with advanced liver fibrosis and hepatocellular carcinoma in South Texas Hispanics. Cancer Epidemiol Biomarkers Prev 30(9):1643-1651, 2021. e-Pub 2021. PMID: 34155064.
- Rechis R, Oestman KB, Caballero E, Brewster A, Walsh MT, Hawk E, et al. Be Well Communities™: Mobilizing communities to promote wellness and stop cancer before it starts. Cancer Causes Control 32(8):859-870, 2021. e-Pub 2021. PMID: 34037915.
- Hawk ET, Maresso KC. The ASPREE trial: An unanticipated stimulus for greater precision in prevention?. J Natl Cancer Inst 113(3):221-222, 2021. e-Pub 2021. PMID: 32778864.
- Guimarães DP, Mantuan LA, de Oliveira MA, Junior RLH, Mafra da Costa A, Hawk ET, et al. The performance of colorectal cancer screening in Brazil: the first two years of the implementation program in Barretos Cancer Hospital. Cancer Prev Res (Phila) 14(2):241-252, 2021. e-Pub 2021. PMID: 32998941.
- Tami-Maury I, Suchil L, Reynales-Shigematsu LM, Garcia-Gomez L, Chen M, Hawk E, et al. Cross-sectional survey for assessing cancer care providers' characteristics and attitudes on smoking cessation in Colombia and Mexico. BMJ Open 11(2):e041447, 2021. e-Pub 2021. PMID: 33526497.
- Torres HA, Lok AS, Suarez-Almazor ME, Warneke CL, Kaseb A, Hawk ET, et al. Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: A cross-sectional study. Support Care Cancer 29(1):97-105, 2021. e-Pub 2021. PMID: 32314052.
- Kripke M, Brody JG, Hawk E, Hernandez AB, Hoppin PJ, Rudel RA, et al. Rethinking environmental carcinogenesis. Cancer Epidemiol Biomarkers Prev 29(10):1870-1875, 2020. e-Pub 2020. PMID: 33004408.
- Davis JS, Kanikarla-Marie P, Gagea M, Yu PL, Fang D, Hawk E, et al. Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. BMC Cancer 20(1):871, 2020. e-Pub 2020. PMID: 32912193.
- Liao Y, Basen-Engquist KM, Urbauer DL, Bevers TB, Hawk E, Schembre SM. Using continuous glucose monitoring to motivate physical activity in overweight and obese adults: A pilot study. Cancer Epidemiol Biomarkers Prev 29(4):761-768, 2020. e-Pub 2020. PMID: 32066620.
- Abu-Sbeih H, Ali FS, Qiao W, Lum P, Shafi MA, Hawk E, et al. Patients with non-colorectal cancers may be at elevated risk of colorectal neoplasia. J Cancer 11(11):3192-3198, 2020. e-Pub 2020. PMID: 32231724.
- Chido-Amajuoyi OG, Mantey D, Cunningham S, Yu R, Kelder S, Hawk E, et al. Characteristics of US adults attempting tobacco use cessation using e-cigarettes. Addict Behav 100:106123, 2020. e-Pub 2020. PMID: 31605837.
- Hawk ET, Colbert Maresso K. E-Cigarettes: Unstandardized, under-regulated, understudied - and unknown health and cancer risks. Cancer Res 79(24):6079-6083, 2019. e-Pub 2019. PMID: 31658978.
- Fokom Domgue J, Baker E, Manjuh F, Lopez M, Welty T, Cameroon Cervical Cancer Prevention ECHO collaborative group, et al. Connecting frontline providers in Africa with distant experts to improve patients' outcomes through Project ECHO: a successful experience in Cameroon. Int J Gynecol Cancer 29(9):1446-1447, 2019. e-Pub 2019. PMID: 31118215.
- Coletta AM, Marquez G, Thomas P, Thoman W, Bevers T, Hawk E, et al. Clinical factors associated with adherence to aerobic and resistance physical activity guidelines among cancer prevention patients and survivors. PLoS One 14(8):e0220814, 2019. e-Pub 2019. PMID: 31369653.
- Hernandez M, Hernández-Valero MA, García-Prieto C, Patterson DG, Hajek RA, Hawk E, et al. A pilot study evaluating organochlorine and organophosphate pesticide exposure in children and adolescents of Mexican descent residing in Hidalgo County, Texas. J Immigr Minor Health 21(4):751-760, 2019. e-Pub 2019. PMID: 30066057.
- Huey RW, Hawk E, Offodile AC. Mind the gap: Precision oncology and its potential to widen disparities. J Oncol Pract 15(6):301-304, 2019. e-Pub 2019. PMID: 31112478.
- Delacruz RGC, Sandoval IT, Chang K, Miller BN, Reyes-Uribe L, Hawk ET, et al. Functional characterization of CNOT3 variants identified in familial adenomatous polyposis adenomas. Oncotarget 10(39):3939-3951, 2019. e-Pub 2019. PMID: 31231471.
- Mackert M, Case K, Lazard A, Oh J, Wagner JH, Hawk E, et al. Building a health communication brand for University of Texas System tobacco control. J Am Coll Health 67(4):291-298, 2019. e-Pub 2019. PMID: 29952736.
- Sivakumar S, San Lucas FA, Jakubek YA, McDowell TL, Lang W, Hawk ET, et al. Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine 42:296-303, 2019. e-Pub 2019. PMID: 30905849.
- Zacharias NM, Ornelas A, Lee J, Hu J, Davis J, Hawk E, et al. Real-time interrogation of aspirin reactivity, biochemistry, and biodistribution by hyperpolarized magnetic resonance spectroscopy. Angew Chem Int Ed Engl 58(13):4179-4183, 2019. e-Pub 2019. PMID: 30680862.
- Cunningham SA, Yu R, Shih T, Giordano S, McNeill LH, Hawk E, et al. Cancer-related risk and beliefs in Texas: Findings from a 2018 population-level survey. Cancer Epidemiol Biomarkers Prev 28(3):486-494, 2019. e-Pub 2019. PMID: 30700446.
- Dahlstrom KR, Sturgis EM, DePinho RA, Hawk E, Baum G. Knowledge about the human papillomavirus vaccine among employees at a tertiary cancer center: room for improvement. J Appl Res Child 10(2):Article 5, 2019. e-Pub 2019.
- Lippman SM, Abate-Shen C, Colbert Maresso KL, Colditz GA, Dannenberg AJ, Hawk ET, et al. AACR white paper: Shaping the future of cancer prevention - a roadmap for advancing science and public health. Cancer Prev Res (Phila) 11(12):735-778, 2018. e-Pub 2018. PMID: 30530635.
- Chang K, Willis JA, Reumers J, Taggart MW, San Lucas FA, Hawk ET, et al. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Ann Oncol 29(10):2061-2067, 2018. e-Pub 2018. PMID: 30412224.
- Frech S, Muha CA, Stevens LM, Trimble EL, Brew R, Hawk ET, et al. Perspectives on strengthening cancer research and control in Latin America through partnerships and diplomacy: Experience of the National Cancer Institute's Center for Global Health. J Glob Oncol 2018(4):1-11, 2018. e-Pub 2018. PMID: 30241245.
- Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, et al. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev 37(2-3):439-454, 2018. e-Pub 2018. PMID: 30112590.
- Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Hawk ET, et al. Immune profiling of premalignant lesions in patients with Lynch syndrome. JAMA Oncol 4(8):1085-1092, 2018. e-Pub 2018. PMID: 29710228.
- Lin SH, Raju GS, Huff C, Ye Y, Gu J, Hawk E, et al. The somatic mutation landscape of premalignant colorectal adenoma. Gut 67(7):1299-1305, 2018. e-Pub 2018. PMID: 28607096.
- Golemis EA, Scheet P, Beck TN, Scolnick E, Hunter DJ, Hawk E, et al. Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32(13-14):868-902, 2018. e-Pub 2018. PMID: 29945886.
- Foxhall L, Moreno M, Hawk E. MD Anderson's population health approaches to cancer prevention. Tex Med 114(2):34-41, 2018. e-Pub 2018. PMID: 29393960.
- Sivakumar S, San Lucas FA, McDowell TL, Lang W, Xu L, Hawk ET, et al. Genomic landscape of atypical adenomatous hyperplasia reveals divergent modes to lung adenocarcinoma. Cancer Res 77(22):6119-6130, 2017. e-Pub 2017. PMID: 28951454.
- Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Hawk E, et al. Estrogen replacement reduces risk and increases survival times of women with hepatocellular carcinoma. Clin Gastroenterol Hepatol 15(11):1791-1799, 2017. e-Pub 2017. PMID: 28579181.
- Gausachs M, Borras E, Chang K, González S, Azuara D, Hawk E T, et al. Mutational heterogeneity in APC and KRAS arises at the crypt level and leads to polyclonality in early colorectal tumorigenesis. Clin Cancer Res 23(19):5936-5947, 2017. e-Pub 2017. PMID: 28645942.
- Lopez MS, Baker ES, Milbourne AM, Gowen RM, Rodriguez AM, Hawk ET, et al. Project ECHO: A telementoring program for cervical cancer prevention and treatment in low-resource settings. J Glob Oncol 3(5):658-665, 2017. e-Pub 2017. PMID: 29094102.
- Menter DG, Kopetz S, Hawk E, Sood AK, Loree JM, Gresele P, et al. Platelet "first responders" in wound response, cancer, and metastasis. Cancer Metastasis Rev 36(2):199-213, 2017. e-Pub 2017. PMID: 28730545.
- Ornelas A, Zacharias-Millward N, Menter DG, Davis JS, Lichtenberger L, Hawk E, et al. Beyond COX-1: The effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev 36(2):289-303, 2017. e-Pub 2017. PMID: 28762014.
- Hurd TC, Kaplan CD, Cook ED, Chilton JA, Lytton JS, Hawk ET, et al. Building trust and diversity in patient-centered oncology clinical trials: An integrated model. Clin Trials 14(2):170-179, 2017. e-Pub 2017. PMID: 28166647.
- Davis JS, Lee HY, Kim J, Advani SM, Peng HL, Hawk ET, et al. Use of non-steroidal anti-inflammatory drugs in US adults: Changes over time and by demographic. Open Heart 4(1):e000550, 2017. e-Pub 2017. PMID: 28674622.
- Maresso KC, Hawk E. Cancer prevention recommendations: impact of adherence. Semin Oncol Nurs 32(3):306-13, 2016. e-Pub 2016. PMID: 27539284.
- Hawk ET. Ernest Hawk discusses the NCI-designated cancer centers' joint statement on the HPV vaccine. Oncology (Williston Park) 30(7):599-600, 2016. e-Pub 2016. PMID: 27422108.
- Wu X, Hildebrandt MA, Ye Y, Chow WH, Gu J, Hawk ET, et al. Cohort Profile: The MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC). Int J Epidemiol 45(3):713-713F, 2016. e-Pub 2016. PMID: 26686840.
- Borras E, San Lucas FA, Chang K, Zhou R, Masand G, Hawk ET, et al. Genomic landscape of colorectal mucosa and adenomas. Cancer Prev Res (Phila) 9(6):417-427, 2016. e-Pub 2016. PMID: 27221540.
- DePinho RA, Hawk E. Cancer prevention in developing countries: a vision for preserving health in Mexico. Salud Publica Mex 58(2):93-96, 2016. e-Pub 2016. PMID: 27557366.
- Hildebrandt MA, Reyes ME, Lin M, He Y, Nguyen SV, Hawk ET, et al. Germline genetic variants in the Wnt/beta-catenin pathway as predictors of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 25(3):540-546, 2016. e-Pub 2016. PMID: 26809274.
- Umar A, Steele VE, Menter DG, Hawk ET. Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. Semin Oncol 43(1):65-77, 2016. e-Pub 2016. PMID: 26970125.
- Lynch PM, Burke CA, Phillips R, Morris JS, Slack R, Hawk E, et al. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Gut 65(2):286-295, 2016. e-Pub 2016. PMID: 25792707.
- Tsai KY, Hawk ET. When "Effective" Prevention Agents Fail to Elicit Anticipated Effects: Challenges in Trial Design. Cancer Prev Res (Phila) 9(2):125-127, 2016. e-Pub 2016. PMID: 26714773.
- Chitsazzadeh V, Coarfa C, Drummond JA, Nguyen T, Joseph A, Hawk ET, et al. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun 7:12601, 2016. e-Pub 2016. PMID: 27574101.
- Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET. Molecular cancer prevention: Current status and future directions. CA Cancer J Clin 65(5):345-383, 2015. e-Pub 2015. PMID: 26284997.
- Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, Hawk E, et al. Obesity early in adulthood increases risk but does not affect outcomes of Hepatocellular Carcinoma. Gastroenterology 149(1):119-129, 2015. e-Pub 2015. PMID: 25836985.
- Menter DG, Patterson SL, Logsdon CD, Kopetz S, Sood A, Hawk ET. Convergence of Nanotechnology and Cancer Prevention: Are We There Yet?. Cancer Prev Res (Phila) 7(10):973-992, 2014. e-Pub 2014. PMID: 25060262.
- Satcher RL, Bogler O, Hyle L, Lee A, Simmons A, Williams R, Hawk E, Matin S, Brewster AM. Telemedicine and telesurgery in cancer care: Inaugural conference at MD Anderson Cancer Center. J Surg Oncol 110(4):353-359, 2014. e-Pub 2014. PMID: 24889208.
- Volk RJ, Hawk E, Bevers TB. Should CMS cover lung cancer screening for the fully informed patient?. JAMA 312(12):1193-4, 2014. e-Pub 2014. PMID: 25247511.
- Akiyama J, Akiyama J, Alexandre L, Alexandre L, Baruah A, Baruah A, Buttar N, Buttar N, Chandra R, Chandra R, Hawk E, Hawk E, et al, et al. Strategy for prevention of cancers of the esophagus. Ann N Y Acad Sci 1325(1):108-26, 2014. e-Pub 2014. PMID: 25266020.
- Herbst RS, Hobin JA, Gritz ER, on Tobacco WCFTAS, Cancer [Hawk E, WK] H. AACR celebrates 50 years of tobacco research and policy. Clin Cancer Res 20(7):1709-18, 2014. e-Pub 2014. PMID: 24691637.
- Hawk ET, Habermann EB, Ford JG, Wenzel JA, Brahmer JR, Chen MS, et al. Five National Cancer Institute-designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials: A current view and opportunities for improvement. Cancer 120 Suppl S7:1113-1121, 2014. e-Pub 2014. PMID: 24643649.
- Xu E, Gu J, Hawk ET, Wang KK, Lai M, Huang M, et al. Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis 34(12):2750-6, 2013. e-Pub 2013. PMID: 23996928.
- Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG, APC Trial Collaborators APC, Kubo M, et al.. Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res 19(23):6430-7, 2013. e-Pub 2013. PMID: 24084763.
- Hassan MM, Kaseb A, Etzel CJ, El-Serag H, Spitz MR, Chang P, Hale KS, Liu M, Rashid A, Shama M, Abbruzzese JL, Loyer EM, Kaur H, Hassabo HM, Vauthey JN, Wray CJ, Hassan BS, Patt YZ, Hawk E, Soliman KM, Li D. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: Risk and prognosis prediction. Mol Carcinog 52 Suppl 1(SUPPL1):139-47, 2013. e-Pub 2013. PMID: 23776098.
- Coxib, (CNT) Collaboration TNT, Bhala N, Emberson J, Merhi A, Hawk E, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382(9894):769-79, 2013. e-Pub 2013. PMID: 23726390.
- Raju GS, Vadyala V, Slack R, Krishna SG, Ross WA, Hawk E, et al. Adenoma detection in patients undergoing a comprehensive colonoscopy screening. Cancer Med 2(3):391-402, 2013. e-Pub 2013. PMID: 23930215.
- Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hawk E, et al. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila) 6(3):196-205, 2013. e-Pub 2013. PMID: 23466817.
- Kumar NB, Dhurandhar M, Aggarwal B, Anant S, Daniel K, Hawk E, et al. Proceedings of the Indo-U.S. bilateral workshop on accelerating botanicals/biologics agent development research for cancer chemoprevention, treatment, and survival. Cancer Med 2(1):108-15, 2013. e-Pub 2013. PMID: 24279005.
- Patterson SL, Maresso KC, Hawk E. Cancer chemoprevention, successes and failures. Clin Chem 59(1):94-101, 2013. e-Pub 2013. PMID: 23150056.
- Lin M, Eng C, Hawk ET, Huang M, Lin J, Gu J, et al. Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. Cancer 118(24):6188-6198, 2012. e-Pub 2012. PMID: 22673945.
- Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, Hawk E, et al. Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminases. J Natl Cancer Inst 104(20):1599-611, 2012. e-Pub 2012. PMID: 23073549.
- Dai J, Gu J, Huang M, Eng C, Kopetz ES, Hawk E, et al. GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. Carcinogenesis 33(7):1327-31, 2012. e-Pub 2012. PMID: 22505654.
- Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Hawk ET, et al. Genetic polymorphisms in MicroRNA-Related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res 18(14):3982-91, 2012. e-Pub 2012. PMID: 22661538.
- Cialdella-Kam L, Sabado P, Bispeck MK, Silverman S, Bernstein L, Hawk E, et al. Implementing Cancer Prevention into Clinical Practice. J Cancer Educ 27(Suppl 2):S136-43, 2012. e-Pub 2012. PMID: 22367592.
- Lin M, Eng C, Hawk E, Huang M, Greisinger AJ, Gu J, et al. Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. Carcinogenesis 33(4):841-7, 2012. e-Pub 2012. PMID: 22318908.
- Arber N, Lieberman D, Wang TC, Zhang R, Sands GH, Hawk ET, et al. The APC and PreSAP Trials: A Post Hoc Noninferiority Analysis Using a Comprehensive New Measure for Gastrointestinal Tract Injury in 2 Randomized, Double-Blind Studies Comparing Celecoxib and Placebo. Clin Ther 34(3):569-79, 2012. e-Pub 2012. PMID: 22386831.
- Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, PLCO Project Team, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104(2):125-32, 2012. e-Pub 2012. PMID: 22228146.
- Ross W, Lynch P, Raju G, Rodriguez A, Burke T, Hawk E, et al. Biomarkers, bundled payments, and colorectal cancer care. Genes Cancer 3(1):16-22, 2012. e-Pub 2012. PMID: 22893787.
- Lin J, Forman MR, Wang J, Grossman HB, Chen M, Hawk ET, et al. Intake of red meat and heterocyclic amines, metabolic pathway genes, and bladder cancer risk. Int J Cancer 131(8):1892-1903, 2012. e-Pub 2012. PMID: 22261697.
- Chan AT, Hsu M, Zauber AG, Hawk ET, Bertagnolli MM. The Influence of UGT1A6 Variants and Aspirin Use in a Randomized Trial of Celecoxib for Prevention of Colorectal Adenoma. Cancer Prev Res (Phila) 5(1):61-72, 2012. e-Pub 2012. PMID: 22030088.
- Fischer SM, Hawk ET, Lubet RA. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila) 4(11):1728-35, 2011. e-Pub 2011. PMID: 21778329.
- Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM. C-reactive Protein and Risk of Colorectal Adenoma According to Celecoxib Treatment. Cancer Prev Res (Phila) 4(8):1172-80, 2011. e-Pub 2011. PMID: 21816845.
- Wu X, Patterson S, Hawk E. Chemoprevention-history and general principles. Best Pract Res Clin Gastroenterol 25(4-5):445-59, 2011. e-Pub 2011. PMID: 22122762.
- Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, PLCO Project Team, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305(22):2295-303, 2011. e-Pub 2011. PMID: 21642681.
- Lin M, Hawk E, Huang M, Lin J, Gu J, Ellis LM, et al. Identification of polymorphisms in ultraconserved elements (UCEs) associated with clinical outcomes in patients (pts) with stage II/III colorectal cancer (CRC). J Clin Oncol 29(15_suppl):3529, 2011. e-Pub 2011. PMID: 22673945.
- Gu J, Ajani JA, Hawk ET, Ye Y, Lee JH, Bhutani MS, et al. Chromosomal Aberrations Predict Malignant Progression of Esophageal Adenocarcinoma: a Genome-wide High-Density SNP Array Analysis. Cancer Prev Res (Phila) 3(9):1176-86, 2010. e-Pub 2010. PMID: 20651033.
- Brewster AM, Patterson SL, Forman MR, Hughes-Halbert C, Limburg PJ, Hawk ET, et al. Conference Report: Eighth Annual AACR International Conference on Frontiers in Cancer Prevention Research. Cancer Prev Res (Phila Pa) 3(8):1044-8, 2010. e-Pub 2010. PMID: 20663980.
- Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M, et al. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol 105(6):1437-43, 2010. e-Pub 2010. PMID: 20234350.
- Hawk E, Patterson S. Modelling a dream: the molecular prevention of pancreatic cancer. Gut 59(5):566-8, 2010. e-Pub 2010. PMID: 20427387.
- Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG. Statin Use and Colorectal Adenoma Risk: Results from the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa) 3(5):588-96, 2010. e-Pub 2010. PMID: 20403998.
- Lippman SM, Hawk ET. Cancer prevention: from 1727 to milestones of the past 100 years. Cancer Res 69(13):5269-84, 2009. e-Pub 2009. PMID: 19491253.
- Chan AT, Zauber AG, Meier H, Breazna A, Hunter DJ, Hawk ET, et al. Cytochrome P450 2C9 Variants Influence Response to Celecoxib for Prevention of Colorectal Adenoma. Gastroenterology 136(7):2127-2136.e1, 2009. e-Pub 2009. PMID: 19233181.
- Mutch MG, Schoen RE, Fleshman JW, Rall CJ, Dry S, Hawk E, et al. A multicenter study of prevalence and risk factors for aberrant crypt foci. Clin Gastroenterol Hepatol 7(5):568-74, 2009. e-Pub 2009. PMID: 19418605.
- Bertagnolli MM, Bertagnolli MM, Eagle CJ, Eagle CJ, Zauber AG, Zauber AG, Redston M, Redston M, Breazna A, Breazna A, Hawk ET, Hawk ET, et al, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa) 2(4):310-21, 2009. e-Pub 2009. PMID: 19336730.
- Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, PLCO Project Team, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310-9, 2009. e-Pub 2009. PMID: 19297565.
- Hawk E, Guillem JG. Improving the Vision of Colonoscopy: Does the Fine Print Really Matter?. Cancer Prev Res (Phila) 1(7):495-498, 2008. e-Pub 2008. PMID: 19138997.
- Srivastava S, Gray JW, Reid BJ, Grad O, Greenwood A, Hawk ET, et al. Translational Research Working Group developmental pathway for biospecimen-based assessment modalities. Clin Cancer Res 14(18):5672-7, 2008. e-Pub 2008. PMID: 18794074.
- Hawk ET, Greenwood A, Gritz ER, McTiernan A, Sellers T, Hursting SD, et al. The Translational Research Working Group developmental pathway for lifestyle alterations. Clin Cancer Res 14(18):5707-13, 2008. e-Pub 2008. PMID: 18794079.
- Hawk ET, Matrisian LM, Nelson WG, Dorfman GS, Stevens L, Kwok J, et al. The Translational Research Working Group developmental pathways: introduction and overview. Clin Cancer Res 14(18):5664-71, 2008. e-Pub 2008. PMID: 18612047.
- Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial. Cancer Prev Res (Phila Pa) 1(1):32-38, 2008. e-Pub 2008. PMID: 18841250.
- Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Hawk ET, et al. Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) 1(1):21-31, 2008. e-Pub 2008. PMID: 19138933.
- Hawk ET, Viner JL. Statins in esophageal cancer cell lines: promising lead?. Am J Gastroenterol 103(4):838-41, 2008. e-Pub 2008. PMID: 18371147.
- Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Hawk E, et al. Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials The Cross Trial Safety Analysis. Circulation 117(16):2104-13, 2008. e-Pub 2008. PMID: 18378608.
- Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Hawk E, et al. Secondary chemoprevention of Barrett's Esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 99(7):545-557, 2007. e-Pub 2007. PMID: 17405999.
- Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Hawk ET, et al. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark 3(1):1-33, 2007. e-Pub 2007. PMID: 17655039.
- Hawk E, Viner JL. What is the future of oncology? National Cancer Institute initiatives to improve research, development, and implementation in cancer prevention and treatment. Semin Oncol 33(6 Suppl 11):S6-S9, 2006. e-Pub 2006. PMID: 17178278.
- Hawk ET, Viner JL. Do statins prevent cancer?. Nat Clin Pract Oncol 3(9):478-9, 2006. e-Pub 2006. PMID: 16955084.
- Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Hawk E, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114(10):1028-1035, 2006. e-Pub 2006. PMID: 16943394.
- Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Hawk ET, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873-84, 2006. e-Pub 2006. PMID: 16943400.
- Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Hawk ET, et al. Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population. Cancer Res 66(13):6851-60, 2006. e-Pub 2006. PMID: 16818663.
- Glebov OK, Rodriguez LM, Lynch P, Patterson S, Lynch H, Hawk E, et al. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol Biomarkers Prev 15(7):1382-1391, 2006. e-Pub 2006. PMID: 16835340.
- Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Hawk ET, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res 12(12):3661-97, 2006. e-Pub 2006. PMID: 16778094.
- Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, Hawk ET, et al. Selenomethionine treatment does not alter gene expression in normal squamous esophageal mucosa in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev 15(5):1046-7, 2006. e-Pub 2006. PMID: 16702392.
- Jankowski JA, Hawk ET. A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. Nat Clin Pract Gastroenterol Hepatol 3(2):101-11, 2006. e-Pub 2006. PMID: 16456576.
- Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 5(12):930-42, 2005. e-Pub 2005. PMID: 16341084.
- Limburg PJ, Wei W, Ahnen DJ, Qiao Y, Hawk ET, Wang G, et al. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology 129(3):863-73, 2005. e-Pub 2005. PMID: 16143126.
- Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Hawk E, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071-80, 2005. e-Pub 2005. PMID: 15713944.
- Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol 23(2):378-91, 2005. e-Pub 2005. PMID: 15637400.
- Hawk ET, Umar A, Richmond E, Viner JL. Prevention and therapy of colorectal cancer. Med Clin North Am 89(1):85-110, viii, 2005. e-Pub 2005. PMID: 15527810.
- Hawk ET, Umar A, Lubet RA, Kopelovich L, Viner JL. Can animal models help us select specific compounds for cancer prevention trials?. Recent Results Cancer Res 166:71-87, 2005. e-Pub 2005. PMID: 15648184.
- Lippman SM, Levin B, Brenner DE, Gordon GB, Aldige CR, Hawk E, et al. Cancer prevention and the American Society of Clinical Oncology. J Clin Oncol 22(19):3848-51, 2004. e-Pub 2004. PMID: 15353541.
- Lam S, leRiche JC, McWilliams A, Macaulay C, Dyachkova Y, Hawk E, et al. A randomized phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 10(19):6502-11, 2004. e-Pub 2004. PMID: 15475437.
- Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 24(5B):3177-84, 2004. e-Pub 2004. PMID: 15510608.
- Jacoby RF, Cole CE, Hawk ET, Lubet RA. Ursodeoxycholate/sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology 127(3):838-44, 2004. e-Pub 2004. PMID: 15362039.
- Lao CD, Backoff P, Shotland LI, McCarty D, Eaton T, Hawk ET, et al. Irreversible ototoxicity associated with difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 13(7):1250-2, 2004. e-Pub 2004. PMID: 15247138.
- Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Hawk ET, et al. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 13(6):920-7, 2004. e-Pub 2004. PMID: 15184247.
- Hawk ET, Umar A, Viner JL. Colorectal cancer chemoprevention--an overview of the science. Gastroenterology 126(5):1423-47, 2004. e-Pub 2004. PMID: 15131803.
- Xiao Z, Luke BT, Izmirlian G, Umar A, Lynch PM, Hawk ET, et al. Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res 64(8):2904-9, 2004. e-Pub 2004. PMID: 15087410.
- Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Hawk ET, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch Syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261-8, 2004. e-Pub 2004. PMID: 14970275.
- Umar A, Risinger JI, Hawk ET, Barrett JC. Testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer 4(2):153-8, 2004. e-Pub 2004. PMID: 14964310.
- Viner JL, Hawk E. Commentary on Chan, et al. N Am Menopause Soc J 11(3), 2004. e-Pub 2004.
- Anderson WF, Umar A, Hawk ET. Cyclooxygenase inhibition in cancer prevention and treatment. Expert Opin Pharmacother 4(12):2193-204, 2003. e-Pub 2003. PMID: 14640918.
- Hawk ET, Viner JL. Aspirin: still learning about the wonder drug. Gut 52(11):1535-6, 2003. e-Pub 2003. PMID: 14570718.
- Sabichi AL, Demierre MF, Hawk ET, Lerman CE, Lippman SM. Frontiers in cancer prevention research. Cancer Res 63(18):5649-55, 2003. e-Pub 2003. PMID: 14522879.
- Glebov OK, Rodriguez LM, Nakahara K, Jenkins J, Cliatt J, Hawk E, et al. Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev 12(8):755-62, 2003. e-Pub 2003. PMID: 12917207.
- Umar A, Viner JL, Anderson WF, Hawk ET. Development of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol 26(4):S48-57, 2003. e-Pub 2003. PMID: 12902856.
- Steele VE, Hawk ET, Viner JL, Lubet RA. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res 523-524:137-44, 2003. e-Pub 2003. PMID: 12628511.
- Hawk ET, Viner J, Richmond E, Umar A. Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention. Cancer Chemother Biol Response Modif 21:759-89, 2003. e-Pub 2003. PMID: 15338773.
- Heath EI, Canto MI, Wu TT, Piantadosi S, Hawk E, Unalp A, et al. Chemoprevention for Barrett's esophagus trial. Design and outcome measures. Dis Esophagus 16(3):177-86, 2003. e-Pub 2003. PMID: 14641306.
- Hawk E, Viner JL, Umar A, Anderson WF, Sigman C, Guyton KZ. Cancer and the cyclo-oxygenase enzyme: implications for treatment and prevention. Amer J Cancer 2:27-55, 2003. e-Pub 2003.
- Viner JL, Umar A, Hawk ET. Chemoprevention of colorectal cancer: problems, progress, and prospects. Gastroenterol Clin North Am 31(4):971-99, 2002. e-Pub 2002. PMID: 12489273.
- Hawk ET, Limburg PJ, Viner JL. Epidemiology and prevention of colorectal cancer. Surg Clin North Am 82(5):905-41, 2002. e-Pub 2002. PMID: 12507200.
- Anderson WF, Guyton KZ, Hiatt RA, Vernon SW, Levin B, Hawk E. Colorectal cancer screening for persons at average risk. J Natl Cancer Inst 94(15):1126-1133, 2002. e-Pub 2002. PMID: 12165637.
- Lam S, MacAulay C, Le Riche JC, Dyachkova Y, Coldman A, Hawk E, et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 94(13):1001-9, 2002. e-Pub 2002. PMID: 12096085.
- Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50(6):857-60, 2002. e-Pub 2002. PMID: 12010890.
- Umar A, Viner JL, Richmond E, Anderson WF, Hawk ET. Chemoprevention of colorectal carcinogenesis. Int J Clin Oncol 7(1):2-26, 2002. e-Pub 2002. PMID: 11942045.
- Anderson WF, Umar A, Viner JL, Hawk ET. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des 8(12):1035-62, 2002. e-Pub 2002. PMID: 11945150.
- Umar A, Viner JL, Hawk ET. The future of colon cancer prevention. Ann N Y Acad Sci 952:88-108, 2001. e-Pub 2001. PMID: 11795446.
- Dimitrov NV, Leece CM, Tompkins ER, Seymour E, Bennink M, Hawk E, et al. Oltipraz concentrations in plasma, buccal mucosa cells, and lipids: pharmacological studies. Cancer Epidemiol Biomarkers Prev 10(3):201-8, 2001. e-Pub 2001. PMID: 11303588.
- Anderson WF, Hawk E, Berg CD. Secondary chemoprevention of upper aerodigestive tract tumors. Semin Oncol 28(1):106-20, 2001. e-Pub 2001. PMID: 11254870.
- Hawk ET, Hawk ET, Viner JL, Viner JL, Anderson BF, Anderson BF. Development of COX inhibitors as cancer chemopreventives. ASCO Educational Book:28-37, 2001. e-Pub 2001.
- Kelloff GJ, Sigman CC, Hawk ET, Johnson KM, Crowell JA, Guyton KZ. Surrogate end-point biomarkers in chemopreventive drug development. IARC Sci Publ 154:13-26, 2001. e-Pub 2001. PMID: 11220652.
- Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, et al. Potential use of lipoxygenase inhibitors for cancer chemoprevention. Expert Opin Investig Drugs 9(9):2121-38, 2000. e-Pub 2000. PMID: 11060797.
- Hawk ET, Lippman SM. Primary cancer prevention trials. Hematol Oncol Clin North Am 14(4):809-30, 2000. e-Pub 2000. PMID: 10949775.
- Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342(26):1946-52, 2000. e-Pub 2000. PMID: 10874062.
- Hawk E, Breslow RA, Graubard BI. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev 9(5):523-7, 2000. e-Pub 2000. PMID: 10815699.
- Hawk E, Viner JL, Lawrence JA. Biomarkers as surrogates for cancer development. Curr Oncol Rep 2(3):242-50, 2000. e-Pub 2000. PMID: 11122849.
- Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk ET, et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 60(7):1864-70, 2000. e-Pub 2000. PMID: 10766173.
- Heath EI, Limburg PJ, Hawk ET, Forastiere AA. Adenocarcinoma of the esophagus: risk factors and prevention. Oncology (Williston Park) 14(4):507-14; discussion 518-20, 522-3, 2000. e-Pub 2000. PMID: 10826312.
- Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Hawk ET, et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 130(2 Suppl):467S-471S, 2000. e-Pub 2000. PMID: 10721931.
- Kelloff GJ, Sigman CC, Johnson KM, Boone CW, Greenwald P, Hawk ET, et al. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev 9(2):127-37, 2000. e-Pub 2000. PMID: 10698472.
- van Stolk R, Stoner G, Hayton WL, Chan K, DeYoung B, Hawk E, et al. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res 6(1):78-89, 2000. e-Pub 2000. PMID: 10656435.
- Hawk E, Limburg P, Lubet R. Chemoprevention in hereditary colorectal cancer syndromes. Cancer 86(11 Suppl):2551-63, 1999. e-Pub 1999. PMID: 10630181.
- Hawk E, Lubet R, Limburg P. Chemoprevention in hereditary colorectal cancer syndromes. Cancer 86(11 Suppl):2551-63, 1999. e-Pub 1999. PMID: 10630181.
- McCaskill-Stevens W, Hawk ET, Flynn PJ, Lippman SM. National Cancer Institute--supported cancer chemoprevention research: coming of age. J Clin Oncol 17(11 Suppl):53-62, 1999. e-Pub 1999. PMID: 10630263.
- Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell JA, et al. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 8(5):467-83, 1999. e-Pub 1999. PMID: 10350444.
- Lam S, leRiche JC, Zheng Y, Coldman A, MacAulay C, Hawk E, et al. Sex-related differences in bronchial epithelial changes associated with tobacco smoking. J Natl Cancer Inst 91(8):691-6, 1999. e-Pub 1999. PMID: 10218506.
- Li H, Schut HA, Conran P, Kramer PM, Lubet RA, Hawk E, et al. Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis 20(3):425-30, 1999. e-Pub 1999. PMID: 10190557.
- Shao J, Sheng H, Aramandla R, Pereira MA, Lubet RA, Hawk E, et al. Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 20(2):185-91, 1999. e-Pub 1999. PMID: 10069452.
- Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Boone CW, Hawk ET, et al. Progress in cancer chemoprevention. Ann N Y Acad Sci 889:1-13, 1999. e-Pub 1999. PMID: 10668477.
- Hawk ET, Limburg PJ. Agent development in colorectal cancer chemoprevention: current status and future trends. ASCO Educational Book:193-9, 1999. e-Pub 1999.
- Stoner GD, Budd GT, Ganapathi R, DeYoung B, Kresty LA, Hawk E, et al. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol 470:45-53, 1999. e-Pub 1999. PMID: 10709673.
- Lieberman R, Crowell JA, Hawk ET, Boone CW, Sigman CC, Kelloff GJ. Development of new cancer chemoprevention agents: role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring. Clin Chem 44(2):420-7, 1998. e-Pub 1998. PMID: 9474054.
- Kelloff GJ, Lubet RA, Lieberman R, Eisenhauer K, Steele VE, Hawk ET, et al. Aromatase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 7(1):65-78, 1998. e-Pub 1998. PMID: 9456245.
- Kelloff GJ, Hawk ET, Karp JE, Crowell JA, Boone CW, Steele VE, et al. Progress in clinical chemoprevention. Semin Oncol 24(2):241-52, 1997. e-Pub 1997. PMID: 9129692.
- Hawk E, Doeltz MK, Kelloff GK. Indomethacin - toxicology and safety. Contribution to IARC Handbooks of Cancer Prevention - Non-steroidal Anti-inflammatory Drugs (International Agency for Research on Cancer, Lyon) 1:151-197, 1997. e-Pub 1997.
- Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk ET, Steele VE, et al. Perspectives and progress in development of breast cancer chemopreventive drugs. Prog Clin Biol Res 396:159-83, 1997. e-Pub 1997. PMID: 9108597.
- Kelloff GJ, Hawk ET, Crowell JA, Boone CW, Steele VE, Lubet RA, et al. Perspectives on chemoprevention agent selection and short-term clinical prevention trials. Eur J Cancer Prev 5(2 Suppl):79-85, 1996. e-Pub 1996. PMID: 9061299.
- Kelloff GJ, Hawk ET, Crowell JA, Boone CW, Nayfield SG, Perloff M, et al. Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology (Williston Park) 10(10):1471-84; discussion 1484-8, 1996. e-Pub 1996. PMID: 8905841.
- Rao KV, Detrisac CJ, Steele VE, Hawk ET, Kelloff GJ, McCormick DL. Differential activity of aspirin, ketoprofen, and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 17(7):1435-8, 1996. e-Pub 1996. PMID: 8706245.
- Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet RA, Greenwald P, Hawk ET, Fay JR, Sigman CC. Mechanistic considerations in the evaluation of chemopreventive data. IARC Sci Publ(139):203-19, 1996. e-Pub 1996. PMID: 8923032.
- Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Malone WF, et al. Risk biomarkers and current strategies for cancer chemoprevention. J Cell Biochem Suppl 25:1-14, 1996. e-Pub 1996. PMID: 9027592.
- Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet RA, Hawk ET, et al. New agents for cancer chemoprevention. J Cell Biochem Suppl 26(SUPPL. 26):1-28, 1996. e-Pub 1996. PMID: 9154166.
- Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW, et al. Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem Suppl 63(26 Suppl):54-71, 1996. e-Pub 1996. PMID: 9154168.
- Kelloff G, Boone C, Crowell J, Nayfield S, Hawk E, Steele VE, et al. Development of breast cancer chemopreventive drugs. Breast J 1:271-83, 1995. e-Pub 1995.
- Kelloff GJ, Boone CW, Crowell JA, Nayfield SG, Hawk E, Steele VE, Lubet RA, Sigman CC. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. J Cell Biochem Suppl 59(23 Suppl):1-9, 1995. e-Pub 1995. PMID: 8747372.
Invited Articles
- Cofer J, Hurst AN, Winter T, Moreno M, Cinciripini PM, Hawk E, et al. A comprehensive program to reduce tobacco-related cancers through actions by a national cancer institute-designated cancer center. Cancer Control 29, 2022. e-Pub 2022. PMID: 36373741.
- Maresso KC, Hawk ET. A new year, a healthier you: 5 actions to reduce your cancer risk. Magazine of the National Association of Petroleum Engineers (NAPE)(January 2020):42-44, 2020. e-Pub 2020.
- Colbert Maresso K, Vilar E, Hawk ET. Urinary PGE-M in colorectal cancer: predicting more than risk?. Cancer Prev Res (Phila) 7(10):969-972, 2014. e-Pub 2014. PMID: 25070664.
- Lin J, Wang J, Greisinger AJ, Grossman HB, Forman MR, Hawk ET, et al. Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer. Cancer Prev Res 3(4):505-17, 2010. e-Pub 2010. PMID: 20354165.
- Hawk E, Patterson S. Aspirin: anti-colorectal adenocarcinoma activity in the adjuvant arena?. Future Oncol 6(2):197-200, 2010. e-Pub 2010. PMID: 20146578.
- Hawk E, Patterson S. Statins: assessing their effects on cancer risk. NYP Cancer Prevention Newsletter(14), 2010. e-Pub 2010.
Other Articles
- Varon ML, Reynoso N, Torres JA, Pérez M, Cantú D, Hawk E, et al. An Opportunity for Developing Cancer Prevention Leadership in Mexico. J Cancer Educ, 2024. PMID: 39446268.
Editorials
- Hill, DG, Hawk, E. Decision in Braidwood v. Becerra increases uncertainty in coverage for cancer screenings. Cancer 131(2):e35689, 2025. PMID: 39668522.
- Hawk E, Martch SL. Recent American college of physicians guidance statement for screening average-risk, asymptomatic adults for colorectal cancer. Cancer Prev Res (Phila) 17(1):1-6, 2024. PMID: 38173395.
- Cohen L, Hawk E. It doesn't need to take 25 years: emphasizing cancer prevention and control in President Biden's Cancer Moonshot. JCO Oncol Pract 19(10):831-34, 2023. PMID: 37672725.
- Agbafe V, Berlin NL, Butler CE, Hawk E, Offodile Ii AC. Prescriptions for mitigating climate change-related externalities in cancer care: A surgeon's perspective. J. Clin. Oncol 40(18):1976-1979, 2022. PMID: 35333584.
- Hawk E, Maresso KC. Aspirin use and cancer prevention: long-term data needed on benefits and risks. The ASCO Post, 2019.
- Hawk E, Maresso KC, Brown P. NSAIDs to prevent breast cancer recurrence? An unanswered question. J Natl Cancer Inst 110(9):927-28, 2018. PMID: 29554350.
- Mahon SM, Hawk E. Introduction. Semin Oncol Nurs 32(3):185-6, 2016. PMID: 27539274.
- Vilar E, Maresso KC, Hawk ET. Aspirin for Cancer Prevention: One Step Closer. JAMA Oncol 2(6):770-771, 2016. PMID: 26939883.
- Brenner DE, Hawk E. Trials and tribulations of interrogating biomarkers to define efficacy of cancer risk reductive interventions. Cancer Prev Res (Phila) 6(2):71-3, 2013. PMID: 23333813.
- Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, et al. Cancer epidemiology, biomarkers & prevention, and cancer prevention research: two journals, a common goal. Cancer Epidemiol Biomarkers Prev 17(11):2903-5, 2008. PMID: 18990728.
- Rebbeck TR, Brown PH, Hawk ET, Lerman C, Paskett ED, Sellers TA, et al. Cancer epidemiology, biomarkers & prevention and cancer prevention research: two journals, a common goal. Cancer Prev Res (Phila) 1(6):393-5, 2008. PMID: 19138984.
- Hawk E, Viner JL. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress. Cancer Epidemiol Biomarkers Prev 16(2):185-7, 2007. PMID: 17301246.
- Hawk E, Viner JL. Statins and cancer-beyond the "one drug-one disease" model. N Engl J Med 352(21):2238-9, 2005. PMID: 15917390.
- Hawk E, Viner JL. The critical role of risk-benefit assessments in cancer prevention. Cancer Epidemiol Biomarkers Prev 14(2):297-8, 2005. PMID: 15734949.
- Kelloff GJ, O'Shaughnessy JA, Gordon GB, Hawk ET, Sigman CC. Counterpoint: because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev 12(7):593-6, 2003. PMID: 12869396.
- Hawk ET, Viner JL, Dannenberg A, DuBois RN. COX-2 in cancer--a player that's defining the rules. J Natl Cancer Inst 94(8):545-6, 2002. PMID: 11959883.
- Hawk ET, Viner JL. Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research. Ann Intern Med 134(2):158-60, 2001. PMID: 11177320.
- Hawk E. Patient needs, physician opportunities, and reimbursement align...Can our clinical practices do similarly?. ASCO Daily News.
Abstracts
- Si M, Martch S, Shete S, Hawk E. Abstract LB143: Environmental assessment of alcohol-related policies and practices at US cancer organizations. AACR Annual Meeting 2024 84(7 Suppl):LB143, 2024. e-Pub 2024.
- Salcedo MP, Gowen R, Lopez M, Baker E, Rodriguez AM, Hawk E, et al.. Addressing the high cervical cancer rates along the Texas-Mexico border through community outreach, patient navigation, and provider training/telementoring. 50th Annual Meeting of the Society of Gynecologic Oncology 154(S1):115, 2019. e-Pub 2019.
- Abu-Sbeih H, Ali F, Qiao W, Lum P, Shafi M, Hawk E, et al. Risk of colonic adenoma in patients with non–colorectal cancers. J Clin Oncol 37(15 suppl):e13070, 2019. e-Pub 2019.
- Shalaby AS, Botrus G, Kaseb AO, Li D, Abdel-Wahab R, Hawk E, et al. The Protective Effect of physical activity on Risk of Hepatocellular Carcinoma in USA. J Clin Oncol 34(15 Suppl):e15642, 2016. e-Pub 2016.
- Hassan M, Li D, Kaseb A, Abbruzzese JL, Hassabo H, Hawk E, et al. Early obesity and risk of hepatocellular carcinoma in USA. 52nd Annual Meeting of the Society of Toxicology 132:519, 2013. e-Pub 2013.
- Hawk E. Clinical agent development for colorectal cancer prevention. 3rd International Cancer Research Symposium 2012: Defining & Translating Science for Disease Prevention and Therapy 7:63, 2013. e-Pub 2013.
- Lynch P, Rodriguez-Bigas M, Burke C, Phillips R, Wang X, Hawk E, et al. An international, randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. Digestive Disease Week 2012 75(4 Suppl):AB285, 2012. e-Pub 2012.
- Foxhall L, Patterson S, Silvas E, Galendez M, Furlan E, Hawk E. Comprehensive cancer control plan implementation at an NCI comprehensive cancer center. Innovations in Cancer Prevention and Research Conference, Cancer Prevention and Research Institute of Texas (CPRIT), 2011.
- Peleg S, Shukla V, Mazumdar A, Curley SA, Hawk E, Brown PH, et al. High Dose Vitamin D Suppresses Growth of HCC Cell Lines and Reduces Hepatocyte Proliferation in β2–spectrin+/- Mice. Hepatology 54(4 Suppl):1304A, 2011. e-Pub 2011.
- Lutz TA, Lopez R, Burke CA, Lynch P, Hawk E, Griebel D, et al. Is hearing loss an extracolonic manifestation of FAP?. Am J Gastroenterol 101(Suppl 554):1456, 2006. e-Pub 2006.
- Lynch P, Burke C, Hawk E, Eagle C, Woloj M, Church J, Hasson H, Patterson S, Benfield R, Half E, Miller D, Ayes GD. Colonoscopy in a phase I safety trial of celecoxib in children with FAP. Familial Cancer 4:57, 2005. e-Pub 2005.
- Peterson SK, Askins MA, Watts BG, Burke CA, Hasson H, Hawk E, et al. Family resiliency and functioning among families with APC-positive children. Familial Cancer 4(1 Suppl):49-50, 2005. e-Pub 2005.
- Burke CA, Lynch PM, Phillips R, Hawk E, Church J, Hasson H, et al. Considerations for maximizing randomization in chemoprevention trials in FAP. Familial Cancer 4:76-77, 2005. e-Pub 2005.
- Lynch P, Burke C, Hawk E, Eagle C, Woloj M, Church J, et al. Efficacy and safety in a phase I safety trial of celecoxib in children with FAP. AGA, 2005.
- Burke C, Hawk E, Eagle C, Wolog M, Church J, Hasson H, et al. Design and primary safety outcome in a phase I trial of celecoxib in children with FAP. Familial Cancer 4:77-8 (A P29), 2005. e-Pub 2005.
- Peterson SK, Lynch PM, Burke C, Church J, Hasson H, Hawk E. Psychosocial evaluation of children and parents involved in a phase I study of celecoxib in children with FAP. CGA, 2004. e-Pub 2004.
- Half E, Su LK, Lunagomez S, Steinbach G, Patterson S, Hawk E, et al. Response to celecoxib in familial adenomatous polyposis (FAP) does not depend on genotype or adenoma burden. Digestive Disease Week 2004, 2004.
- Lynch PM, Steinbach G, Hittelman W, Terry N, Frazier M, Hawk E, et al. A phase II chemoprevention trial in HNPCC utilizing a selective cyclooxygenase 2 inhibitor: protocol description and progress to date. J Gastroenterol Hepatol 14(8):A59, 1999. e-Pub 1999.
- Steinbach G, Lynch PM, Phillips R, Wallace M, Hawk E, Gordon G. Effect of celecoxib on colorectal polyps in patients with familial adenomatous polyposis (FAP). Am J Gastroenterol 94(9):440, 1999. e-Pub 1999.
- Yao Z, Jogunoori W, Peleg S, Amdur R, Patel K, Hawk E, et al. Restoration of Key TGF-β signaling Proteins by Vitamin D in Cirrhotic Human Livers with and without Hepatocellular Carcinoma (HCC). AASLD.
- Peleg S, Shetty K, Shukla V, Amdur R, Patel K, Hawk E, et al. Vitamin D as a Chemopreventive Agent for Hepatocellular Carcinoma (HCC). AASLD.
- Hassan M, Abdel-Wahab R, Wolff RA, Botrus G, Shalaby A, Hawk E, et al. Growth Hormone and Hepatocellular Carcinoma. The Liver Meeting 2016 – The 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
- Hassan M, Abdel-Wahab R, Kaseb AO, Shalaby A, Botrus G, Hawk E, et al. Hepatocellular carcinoma screening in high-risk populations in the united states. The Liver Meeting 2016 – The 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
Book Chapters
- Maresso, KC, Basen-Engquist, KM, Hawk, E. Cancer epidemiology, prevention, and survivorship. In: Perioperative Care of the Cancer Patient, 3-14, 2023.
- Bevers T, El-Serag H, Hanash S, Thrift AP, Tsai K, Hawk E, et al. Screening and early detection. In: Abeloff's Clinical Oncology. 6th. Elsevier, 375-98.e7, 2019.
- Basen-Engquist K, Brown P, Coletta AM, Savage M, Maresso KC, Hawk E. Lifestyle and cancer prevention. In: Abeloff's Clinical Oncology. 6th. Elsevier, 337-74, 2019.
- Menter, DG, Davis, JS, Tucker, SC, Hawk, E, Crissman, JD, Sood, AK, et al. Platelets: "First responders" in cancer progression and metastasis. In: Platelets in Thromb. and Non-Thromb. Disord.: Pathophysiol., Pharmacol. and Ther.: an Update. Springer, 1111-32, 2017.
- Colbert Maresso K, Hawk E. Designing the chemoprevention trials of tomorrow: applying lessons learned from past definitive trials. In: Cancer prevention: dietary factors and pharmacology. Humana Press, 265-84, 2013.
- Bevers TB, Brown PH, Maresso KC, Hawk ET. Cancer prevention, screening, and early detection. In: Abeloff's Clinical Oncology. 5th. Elsevier, 322-59, 2013.
- Hawk ET, Patterson SL, Mishra L, Patel KK. Colorectal cancer prevention and aging. In: Cancer and Aging Handbook: Research and Practice. John Wiley & Sons, 85-96, 2012.
- Viner JL, Hawk E, Lippman S. Cancer chemoprevention. In: Cancer epidemiology and prevention. 3rd. Oxford Univ. Press, 1318-40, 2006.
- Hawk E. COX-2 in cancer. In: Targeted cancer therapies, an odyssey: tromsø symposium 2003. Tromso Univ. Press, 92-5, 2003.
- Hawk E, Sigman CC, Kelloff G. Prevention of gastrointestinal cancers. In: Gastrointestinal oncology. Saunders, 205-14, 2003.
- Anderson WF, Umar A, Viner JL, Hawk ET. Potential role of NSAIDs and COX-2 blockade in cancer therapy. In: COX-2 blockade in cancer prevention and therapy. Humana, 313-40, 2003.
- Hawk ET, Viner JL, Umar A. Non-steroidal anti-inflammatory and cyclooxygenase-2 selective inhibitors in clinical cancer prevention trials. In: COX-2: a new target for cancer prevention and treatment. Karger, 210-42, 2003.
- Hawk ET, Viner JL, Limburg PJ. Epidemiology and prevention of colorectal cancer. In: Gastrointestinal oncology. Oxford Univ. Press, 593-634, 2003.
- Viner J, Richmond E, Hawk E, Lawrence J. Chemoprevention. In: The cancer handbook. Nature, 1417-38, 2002.
- Watson AJM, Hawk E, DuBois RN. Chemoprevention of colorectal cancer. In: Gastrointestinal oncology. 1. Saunders, 421-428, 2002.
- Schatzkin A, Goldstein A, Hawk E. Chemo-and dietary prevention of familial cancer: from theory to practice. In: Familial cancer and prevention: molecular epidemiology: a new strategy. Wiley & Sons, 295-301, 1999.
Books (edited and written)
- Hawk E. Holland-Frei Cancer Medicine, 10th edition. Ed(s) 10th. Wiley-Blackwell, 2023.
- Jankowski J, Hawk E. Handbook of gastrointestinal cancer. John Wiley & Sons, 2012.
- Kelloff GJ, Hawk ET, Sigman CC. Cancer chemoprevention. Humana Press, 2005.
- Kelloff GJ, Hawk ET, Sigman CC. Cancer chemoprevention. Humana Press, 2004.
Letters to the Editor
- Tripp MK, Gershenwald JE, Davies MA, Garcia J, Gritz ER, Hawk ET, et al. Assessment of compliance with Texas legislation banning indoor UV tanning by minors. JAMA Dermatol 153: 228-229, 2017.
- Hawk E, Prindiville S, Kelloff G. NSAID trials, sporadic adenomas, and conservative inferences. Gastroenterology 110: 654-5, 1996.
Patents
- Gandjbakhche A, Hattery D, Mulshine J, Smith P, Hawk E, Chernomordik V, Wellner E, and Eidsath A. Probe using Diffuse-Reflectance Spectroscopy. Patent Number: United States Provisional Application #60/238,600.
Selected Presentations & Talks
Local Presentations
- 2019. Houston Business Coalition on Health. Houston, TX, US.
- 2019. Building a Cancer Prevention Program. Houston, TX, US.
- 2018. Aspirin as a Cancer Preventive Agent Existing Evidence & Remaining Questions. Houston, TX, US.
- 2014. EndTobacco Initiative/Institutional Advancement Grand Rounds. Houston, TX, US.
- 2013. Chemoprevention of Colorectal Cancer/Institutional Grand Rounds. Houston, TX, US.
- 2012. Retooling for a Healthier Community with the Affordable Care Act. 9th Annual Symposium. Houston, TX, US.
- 2011. 2011 Cancer Survivorship Research Symposium. Panelist. Houston, Texas, US.
- 2011. Advancing GI Cancer Prevention/Grand Rounds. Houston, TX, US.
- 2009. Tobacco Dependence: Risk, Treatment Strategies and Community Applications/Institutional Grand Rounds. Houston, TX, US.
- 2008. The Development of Anti-inflammatories for Cancer Prevention: From Fame to Flames ... to Phoenix?/Grand Rounds. Houston, TX, US.
- 2006. NCI's Current & Future Commitment to Translational Cancer Research. Translational Science Research Symposium. Baltimore, MD, US.
- 2005. Cancer Chemoprevention. Fundamentals of Clinical Oncology for Public Health Practitioners. Baltimore, MD, US.
- 2004. Clinical Prevention Trial Design - New and Emerging Concepts. Rockville, MD, US.
- 2004. Cancer Chemoprevention with Aspirin - Where We Are, Where We're Going. Third Annual SCORE Symposium. Bethesda, MD, US.
- 2002. Colon Cancer Prevention - What Internists Need to Know/ Medical Grand Rounds. Bethesda, MD, US.
- 2001. Current Standards for Colorectal Cancer Screening - Realizing Prevention's Promise. Tomorrow's Cancer Medicine Today: Latest Developments in Treatment and Prevention of Colorectal Cancer. Bethesda, MD, US.
- 2001. Colorectal Cancer Epidemiology and Prevention. Montgomery County Cancer Crusade Forum. Rockville, MD, US.
- 2000. Colon Cancer Prevention: Turning Current and Future Opportunities into Practice. First Membership Meeting of the Colon Cancer Alliance. Washington, DC, US.
- 2000. Colorectal Cancer Prevention - Current and Future Options. Invited. Baltimore, MD, US.
- 1996. The Agents, Biomarkers, and Cohorts of Cancer Chemoprevention Trials. NCI/USUHS Seminar. Bethesda, MD, US.
Regional Presentations
- 2022. Preneoplastic Conditions as a Model for Early Detection/ Plenary Session. AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer. Austin, TX, US.
- 2019. Healthier Texas Summit. Austin, TX, US.
- 2018. Integrating Cancer Prevention Through Personal & Public Actions: MD Anderson's Approach. Preventive Medicine and Community Health Departmental Seminar Series. Galveston, TX, US.
- 2009. CPRIT Foundation's Policy Roundtable Meeting. Panelist. Austin, Texas, US.
- 2009. Progress in Translational Cancer Prevention. Austin, TX, US.
- 2004. Cancer Chemoprevention - From Emerging to Emerged. Cancer Education Consortium - Fellows Symposium in Cancer Pharmacology. Leesburg, VA, US.
- 2003. Colorectal Cancer Screening & Prevention - Putting Theory into Practice. Arlington, VA, US.
- 2003. Cancer Chemoprevention. Cancer Education Consortium on Pharmacology. Reston, VA, US.
- 2002. Colorectal Cancer: Current and Future Opportunities in Prevention and Treatment. Brown Bag Lunch Seminar. Washington, DC, US.
- 2001. COX-2 Inhibition in Cancer Prevention and Treatment. Invited. 2001 Winter Meeting. Washington, DC, US.
- 2001. COX-2 Inhibitors in Cancer Chemoprevention. Basic Science Conference. Washington, DC, US.
National Presentations
- 2025. Current State of Chemoprevention, from Biology to the Community. Panelist. ASPO 49TH Annual Meeting. Philadelphia, Pennsylvania, US.
- 2022. Panelist, Preneoplasia: Definitions, Precancer Atlas and Resources. AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer. Austin, TX, US.
- 2022. Cancer Prevention and Interception. AACR Annual Meeting 2022. New Orleans, LA, US.
- 2022. Detecting Precancerous Lesions via MCED Testing. AACR Annual Meeting 2022. New Orleans, LA, US.
- 2022. Innovative Approaches for Implementation – Community, Regulatory, and Operational/ Plenary Session. AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer. Austin, TX, US.
- 2022. Panelist, What can we learn from trials that return unexpected results on mortality benefit from early detection biomarkers/tests?. Early Detection of Cancer Conference. Portland, OR, US.
- 2021. Surrogate Endpoints Issues and Opportunities/ Panel. Invited. Virtual, US.
- 2021. Cancer Prevention for the Practicing Clinician: Recommendations for Patients and Families. Invited. 2021 Cancer Care Symposium. Virtual, TX, US.
- 2021. The Possible Future of Liquid Biopsy in Cancer Prevention. Invited. NCI Symposium on Charting the Course of Liquid Biopsy in Precision Prevention and Treatment. Virtual, US.
- 2021. Moderator, Academic-Industry Partnership Forum. Invited. 12th Early Detection Research Network (EDRN) Scientific Workshop. Virtual, US.
- 2021. Overview of NSAIDs with Focus on Coxib in Cancer Prevention. Invited. Think Tank on Aspirin and Non-Steroidal Anti-inflammatory Drugs (NSAIDs) in Cancer Prevention. Virtual, US.
- 2021. Choosing the Population and Endpoints for a Trial. Invited. Cancer Screening Trial Network Workshop. Virtual, US.
- 2020. Universal Cancer Screening Summit. Rochester, MD, US.
- 2019. Addressing the high cervical cancer rates along the Texas-Mexico border through community outreach, patient navigation, and provider training/telementoring. Poster. 50th Annual Meeting of the Society of Gynecologic Oncology. Honolulu, Hawaii, US.
- 2019. Models for Population Health Improvement by Health Care Systems and Partners: Tensions and Promise on the Path Upstream Workshop. Washington, DC, US.
- 2019. Evidence-Based Examples of Effective Cancer Prevention and Control. The Coalition for Better Health at Lower Cost. New York, NY, US.
- 2019. Cancer Prevention for the Practicing Oncologist - Recommendations for Cancer Patients and Their Families. Invited. Banner Health Regional Cancer Conference. Loveland, CO, US.
- 2019. Panelist, Key Challenges in Clinical Trial Data Sharing and Reuse. Invited. Sharing Clinical Trial Data: Challenges and a Way Forward: A Workshop. Washington, D.C, US.
- 2018. Integrating Cancer Prevention Through Personal & Public Actions: MD Anderson's Approach. Fox Chase Cancer Prevention Symposium. Philadelphia, PA, US.
- 2017. Integrating Cancer Prevention Through Personal & Public Actions: MD Anderson's Approach. New Orleans, LA, US.
- 2017. Integrating Cancer Prevention Through Personal & Public Actions: MD Anderson's Approach/Grand Rounds. Omaha, NE, US.
- 2016. Integrating Cancer Prevention Through Personal & Public Actions/Grand Rounds. Invited. Iowa City, IA, US.
- 2016. Cancer Prevention as an Urgent Priority: Driving Progress Through Molecular & Translational Research, as well as Population-Based Actions. Distinguished Scientist Seminar. Mobile, AL, US.
- 2015. Advancing Cancer Prevention & Control as "Plan A". The Sidney Kimmel Comprehensive Cancer Center Visiting Professor Lecture Series. Baltimore, MD, US.
- 2015. Advancing Cancer Prevention & Control as "Plan A". Visiting. Daniel G. Miller Lectureship. New York, NY, US.
- 2014. Advancing Cancer Prevention & Control as Plan A: Perspectives from a Former Cancer Prevention Fellow. Cancer Prevention and Control Colloquia Series. Bethesda, MD, US.
- 2013. The Gold Standard's Impact on Communities. Panelist. CEO Roundtable XII. Cary, North Carolina, US.
- 2013. Prevention in a NCI-designated Cancer Center- Distraction or Distinction?. Omaha, NE, US.
- 2013. Colorectal Cancer Prevention: What We've Learned, Where We're Going, How We'll Get There. Omaha, NE, US.
- 2011. Advancing Population Science Research in Cancer. Rochester, MN, US.
- 2009. The Development of Anti-Inflammatories for Cancer Prevention - From Fame, to Flames, to Phoenix? / Grand Rounds. Madison, WI, US.
- 2009. Development of Anti-inflammatories for Cancer Prevention - From Fame to Flames…to Phoenix?. Chemoprevention Lecture Series. Chicago, IL, US.
- 2009. NSAIDs in Cancer Chemoprevention - From Fame to Flames...to Phoenix?. Tucson, AZ, US.
- 2009. Principles of Cancer Prevention: Interventions that Reduce Cancer Risk and Progression. Johnson City, TN, US.
- 2008. Chemoprevention in the Era of Personalized Medicine: Recent Advances. Panelist. AACR Annual Meeting 2008. San Diego, California, US.
International Presentations
- 2018. Integrating Cancer Prevention Through Personal & Public Actions: MD Anderson's Approach. DKFZ Conference on Preventive Oncology: Facing the Challenges of Cancer Prevention and Early Detection, DE.
- 2012. Molecular Basis of Chemoprevention. 305th Dr. Luis Guerrero Memorial Lecture. Manila, PH.
- 2012. Prevention in a Cancer Center: Revolution or Evolution?. The Gina V. Panuncialman Memorial Lecture. Manila, PH.
Formal Peers
- 2022. Evidence-Based Innovative Cancer Control Programs Accelerating Implementation of Cancer Control Programs in APEC Economies through Innovation and Partnership. Invited. Virtual, US.
- 2019. Strategic Planning Working Group. Invited. Bethesda, MD, US.
- 2019. Cancer Prevention Steering Committee Annual Meeting. Invited. Washington, DC, US.
- 2009. Integrated, Multi-disciplinary Translational Research Across a Disease Spectrum Using the NCI Translational Research Working Group (TRWG) Pathways Model. Invited. Philadelphia, PA, US.
- 2007. Cancer Chemoprevention. Invited. Baltimore, MD, US.
- 2007. The Future of Translational Science in Cancer. Invited. Bethesda, MD, US.
- 2007. Colorectal Cancer Prevention. Invited. Bethesda, MD, US.
- 2006. The Future of Translational Science in Cancer. Invited. Bethesda, MD, US.
- 2006. Cancer Chemoprevention. Invited. Baltimore, MD, US.
- 2006. Translational Research Working Group - Interim Report. Invited. Bethesda, MD, US.
- 2006. The NCI's Translational Research Working Group - Envisioning the Future of Translational Cancer Research. Invited. Washington, DC, US.
- 2006. Translational Research Working Group - Interim Report. Invited. Bethesda, MD, US.
- 2006. The NCI's Translational Research Working Group - Envisioning the Future of Translational Cancer Research. Invited. Washington, DC, US.
- 2006. Translational Research Working Group. Invited. Gaithersburg, MD, US.
- 2006. The Future of Cancer Prevention Research & How to Find Your Place in It. Invited. Bethesda, MD, US.
- 2006. The NCI's Translational Research Working Group - Envisioning the Future of Translational Cancer Research. Invited. Washington, DC, US.
- 2006. The NCI's Translational Research Working Group - Status Report. Invited. Bethesda, MD, US.
- 2005. The Future of Translational Science in Cancer. Invited. Bethesda, MD, US.
- 2004. Esophageal Cancer - Epidemiology, Detection, and Prevention. Invited. Bethesda, MD, US.
- 2003. State of the Science in Clinical Cancer Prevention. Invited. Bethesda, MD, US.
- 2003. Colorectal Cancer - Epidemiology, Detection, and Prevention. Invited. Bethesda, MD, US.
- 2002. DCP Drug Development Program. Invited. Bethesda, MD, US.
- 2002. Colorectal Cancer Chemoprevention. Invited. Bethesda, MD, US.
- 2002. COX-2 as a Molecular Target for Prevention. Invited. Bethesda, MD, US.
- 2002. Colorectal Cancer - Epidemiology, Detection, and Prevention. Invited. Bethesda, MD, US.
- 2002. Phase II Prevention Trials - The Translational Bridge Between Prevention Science and Clinical Benefits. Invited. Bethesda, MD, US.
- 2001. NSAIDs and Cancer Prevention - NCI's Portfolio. Invited. Bethesda, MD, US.
- 2001. Research Gaps, Needs, and Opportunities in Barrett's Esophagus. Invited. Bethesda, MD, US.
- 2001. Intermediate Biomarkers - Uses, Advantages, and Disadvantages as Markers of Preventive Efficacy. Invited. Bethesda, MD, US.
- 2001. Putting Prevention into Practice - Now and In the Future. Invited. Bethesda, MD, US.
- 2001. Colorectal Cancer - Epidemiology, Detection, and Prevention. Invited. Bethesda, MD, US.
- 2001. Prevention and Therapeutic Interventions in Esophageal Carcinogenesis. Invited. Bethesda, MD, US.
- 2000. NCI's Research Portfolio in Barrett's Esophageal Cancer - Etiology, Early Detection, Prevention, and Treatment. Invited, US.
- 2000. Esophageal Cancer - Epidemiology & Prevention. Invited. Bethesda, MD, US.
- 1998. Molecular and Cellular Carcinogenesis - The Process as a Disease. Invited. Bethesda, MD, US.
- 1997. Molecular and Cellular Carcinogenesis - The Process as a Disease. Invited. Bethesda, MD, US.
Grant & Contract Support
| Date: | 2024 - 2027 |
| Title: | Project 80% Colorectal Cancer Screening Program |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Consult |
| ID: | PP250005 |
| Date: | 2022 - 2025 |
| Title: | Project ACCESS: Increasing Access to Cervical Cancer Screening & Treatment Services in Texas |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | PP220037 |
| Date: | 2020 - 2022 |
| Title: | Advances in our understanding of the mechanisms of obesity and radiation in carcinogenesis, and personalized cancer etiology |
| Funding Source: | John Templeton Foundation |
| Role: | Co-I |
| ID: | 61471 |
| Date: | 2020 - 2021 |
| Title: | Be Well Communities(TM): A Model for Cancer Prevention & Control in Underserved Communities |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| ID: | 3P30CA016672-44S5 |
| Date: | 2020 - 2021 |
| Title: | HPV vaccine hesitancy and uptake within The University of Texas System - A catalyst for population-level advances |
| Funding Source: | NIH/NCI |
| Role: | Project Leader |
| Date: | 2020 - 2021 |
| Title: | Cannabis use among cancer patients and survivors: access, use patterns, knowledge, perceived risks and benefits; and interactions with healthcare providers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2019 - 2024 |
| Title: | Project 3: Non-Invasive Assessment of Liver Fibrosis Stage and Progression in Obesity and Diabetes: A Hispanic Population Study |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P50CA217674-01A |
| Date: | 2019 - 2024 |
| Title: | Core Infrastructure Support |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | HHSN261201200034I / 75N91019F00129 |
| Date: | 2019 - 2024 |
| Title: | Collaborative Action Program to Reduce Liver Cancer Mortality in Texas: Collaborative Action Center |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RFA R-19.2-CAP:CAC |
| Date: | 2019 - 2022 |
| Title: | Expansion of cervical cancer prevention services to medically underserved populations through patient outreach, navigation & provider training/telementoring |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Program Director |
| ID: | PP190014 |
| Date: | 2017 - 2021 |
| Title: | INCan Collaborative Development of a Curriculum in Cancer Prevention and Control for the Institute Nacional de Cancerologia in Mexico |
| Funding Source: | CRDF Global |
| Role: | PI |
| ID: | 59-0210-6-004 |
| Date: | 2017 - 2022 |
| Title: | The Role of Methyl Donors in Cancer Risk |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA219983 |
| Date: | 2017 - 2019 |
| Title: | Aspirin-PC for Chemoprevention of Colorectal Cancer |
| Funding Source: | PLX Pharma |
| Role: | Co-I |
| ID: | R42 CA171408-02A1 |
| Date: | 2017 - 2022 |
| Title: | Integrative Analysis of Sequencing Data for Adenoma Development |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1-R01-CA216438-01 |
| Date: | 2016 - 2018 |
| Title: | Administrative Supplements for NCI-designated Cancer Centers to Support Population Health Assessment in Cancer Center Catchment Areas |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 3P30CA016672-41S6 |
| Date: | 2015 - 2017 |
| Title: | Molecular Characterization of Aspirin for Colorectal Cancer Treatment and Prevention |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Date: | 2015 - 2020 |
| Title: | Genome-Wide Association Study in Hepatocellular Carcinoma (GWAS Study) |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator (Year 5) |
| ID: | 1R01CA186566-01A1 |
| Date: | 2015 - 2020 |
| Title: | SPORE in Liver Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator Project 3 |
| Date: | 2015 - 2020 |
| Title: | Multi-Ethnic Cancer Survivorship Cohort |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2014 - 2018 |
| Title: | Improving Cervical Cancer Screening and Prevention in the Lower Rio Grande Valley Through Public Outreach, Patient Navigation, and Telementoring |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Program Director |
| ID: | PP150012 |
| Date: | 2014 - 2016 |
| Title: | Discovering New Targets for Chemoprevention in FAP |
| Funding Source: | NIH/NCI |
| Role: | Significant Contributor |
| ID: | 1R03CA176788-01A1 |
| Date: | 2013 - 2016 |
| Title: | A Double-Blind, Randomized, Phase III Trial of the Safety and Efficacy of CPP-1X/Sulindac Compared with CPP-1X, Sulindac as Single Agents in Patients with FAP and Attenuated FAP |
| Funding Source: | Cancer Prevention Pharmaceuticals |
| Role: | Co-PI |
| Date: | 2013 - 2018 |
| Title: | Gut microbiome: integrating risk pathways in obesity and colorectal neoplasia |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 |
| Date: | 2013 - 2015 |
| Title: | Aspirin-PC for Chemoprevention of Colorectal Cancer |
| Funding Source: | NIH/NCI |
| Role: | Consult |
| ID: | 3R41CA171408-01A1S1 |
| Date: | 2012 - 2017 |
| Title: | Esophagus SPORE: Biology of Barrett's Esophagus and Adenocarcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2012 - 2014 |
| Title: | Use of a FIT-Flu Intervention to Increase Colorectal Cancer Screening Rates in the Houston Metropolitan Area |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-Program Director |
| ID: | PP120207 |
| Date: | 2012 - 2017 |
| Title: | Creation of the MD Anderson Cancer Patient Cohort (MDACPC) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2012 - 2017 |
| Title: | MD Anderson SPORE in Hepatocellular Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2012 - 2016 |
| Title: | A web-based Computational Tool for Prediction of Colorectal Cancer Outcomes |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2012 - 2015 |
| Title: | Implementation of CT Colonography in the Harris County Hospital District for the Diagnostic Evaluation of Patients with Positive FOBT/FIT Test Results |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Significant Contributor |
| Date: | 2011 - 2014 |
| Title: | Chemoprevention of Colon Cancer by Targeting APC-deficient Cells for Apoptosis |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP120280 |
| Date: | 2011 - 2017 |
| Title: | Enhancing Minority Participants in Clinical Trials (EMPaCT): Phase II |
| Funding Source: | NIH/NIMH |
| Role: | Co-PI |
| ID: | 5U24MD006970-06 |
| Date: | 2010 - 2011 |
| Title: | Role of microRNA in Colorectal Cancer Clinical Outcome Prediction: a Genome-wide Analysis |
| Funding Source: | The University of Texas M.D. Anderson Cancer Center |
| Role: | Co-I |
| ID: | Multidisciplinary Research Award |
| Date: | 2010 - 2011 |
| Title: | Chemoprevention of Colon Cancer by Targeting APC-deficient Cells for Apoptosis |
| Funding Source: | The University of Texas M.D. Anderson Cancer Center |
| Role: | Co-I |
| ID: | Multidisciplinary Research Award |
| Date: | 2010 - 2012 |
| Title: | Enhancing Minority Participants in Clinical Trials (EMPaCT) |
| Funding Source: | NIH/NCI |
| Role: | Co-Director |
| ID: | 1RC2MD004797-01 |
| Date: | 2008 - 2024 |
| Title: | Cancer Center Support Grant |
| Funding Source: | NIH/NCI |
| Role: | Member, CCSG Senior Leadership/Associate Director Population Sciences; Director Community Outreach and Engagement; Co-Leader GI Program |
| ID: | 5P30CA016672-44 |
| Date: | 2008 - 2016 |
| Title: | Cellular and Molecular Mechanisms of Gastrointestinal Cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5P01CA130821-06 |
| Title: | Risk Factors of Hepatocellular Carcinoma in the USA |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Title: | Comparative Effectiveness Research Project |
| Funding Source: | AHRQ |
| Role: | PI |
| Title: | Therapeutic Prevention for Colon Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| Title: | MicroRNA and clinical outcome of esophageal cancer: a genome-wide analysis of germline genetic variations and somatic molecular alterations |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| Title: | Development of PC-conjugated Aspirin for Colon Cancer Prevention |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-PI |
Patient Reviews
CV information above last modified July 01, 2025